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Abstract
Identification and Characterization of Protein Kinase C Substrates
in Human Breast Cells

By

Xin Zhao

Advisor: Professor Susan A. Rotenberg
Aberrations in PKC signaling can lead to the development of multiple human diseases and
the most prominent association of PKC with disease has been in tumor growth and
metastasis. PKC and its related pathways have been recognized as promising targets for
blocking the malignancy of breast cancer cells. To better understand PKC-mediated pathway
in breast cancer cells, it is important to identify the cellular substrates of PKC. The main
focus of this work is to identify physiologically relevant cellular substrates of PKC in human
breast cells and to characterize their roles in cancer-related phenotypes. The work to be
described consists of two projects: (1) identification of a new PKC substrate that contributes
to cancer-related phenotypes in human breast cells; (2) characterization of the functional
significance of its phosphorylation by PKC in normal and malignant human breast epithelial
cells.
In the first project, the traceable kinase method was applied to identify potential PKC
substrates in human breast cells. Potential substrates included those proteins that regulate or
serve as effectors for the small GTPases. In light of previous studies showing that small
GTPases play an important role in PKC-induced motility, the present study focused on
proteins deemed to be strong candidate substrates. From ROCK1, CEP4, PAK2 and CLASP1
iv

four candidates, it was demonstrated that CEP4 is in fact an intracellular PKC substrate, as
shown by in vitro kinase assay and intracellular phosphorylation in human breast cells under
DAG-lactone stimulation. CEP4 was found to serve as an intracellular substrate for PKCandby testing the impact on intracellular CEP4 phosphorylation by PKC isoformspecific shRNA reagents or kinase-defective mutants.
In the second project, the functional significance of phospho-CEP4 was investigated in MCF10A cells and MDA-MB-231 cells. Phospho-CEP4 stimulated cell motility, slowed the cell
proliferation rate, and induced filopodia formation. In MCF-10A cells, the phosphorylation of
CEP4 caused its disassociation from Cdc42. Rac1 was shown to participate in phosphoCEP4-induced cell motility. As shown by others, CEP4 does not interact with Rac1 directly.
Phospho-CEP4 might interact with Rac1 directly or associate with another partner to engage
the Rac1 pathway to induce cell migration. This study is the first to identify CEP4 as a PKC
substrate in human breast cells. The demonstrated functional significance of phospho-CEP4
to malignant phenotypes of human breast cells could provide a predictive marker for human
breast cancer.
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Chapter 1: Introduction
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1.1: PKC Structure, Classification, and Regulation
Ca2+-activated, phospholipid-dependent protein kinase (PKC) is defined by a structurallyrelated family of serine/threonine protein kinases that are involved in several biological
processes including proliferation, differentiation, apoptosis, adhesion and migration. All
members contain a highly conserved kinase domain and regulatory domain. The kinase
domain resides in the C-terminal half of the protein and consists of motifs that are required
for ATP/substrate binding and catalysis. The regulatory domain is contained within the amino
terminal half of the protein and is defined by an auto-inhibitory pseudo-substrate domain and
one or two discrete membrane targeting domains; a C1 domain that binds diacylglycerol
(DAG) or phorbol ester, and a C2 domain that binds Ca2+ (Steinberg, 2008). This family is
sub-classified into three groups of isoforms based on their cofactor requirements for
activation and corresponding structural differences in their regulatory domain (Figure 1.1)
(Newton, 2001). The three subclasses are: (1) conventional PKCs (cPKCs) that contains both
a C1 domain that functions as a DAG binding site and a C2 domain that binds Ca2+; (2) novel
PKCs (nPKCs) are structurally similar to the cPKCs, except that they lack a Ca2+ binding site
but can be stimulated by DAG; (3) atypical PKCs (aPKCs) also lack a Ca2+-binding C2
domain and have an atypical C1 domain that makes them insensitive to DAG but responsive
to other lipids such as arachidonic acid and ceramide. The group of conventional PKC
isoforms is the most highly studied and best understood subclass.
The PKC family transduces cell signals by promoting lipid hydrolysis (Nishizuka, 1995).
Many known membrane receptors transmit intracellular signals through activation of PKC
(Kenny et al., 2007; Lee and Bell, 1991). One known pathway for PKC activation is
described in Figure 1.2 (Koivunen et al., 2006). An external signal activates a G-ProteinCoupled Receptor (GPCR), which activates the GTPase enzyme phospholipase C (PLC).
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PLC cleaves phosphoinositol-4,5-bisphosphate (PIP2) into DAG and inositol-1,4,5trisphosphate (IP3). IP3 interacts with a calcium channel in the endoplasmic reticulum (ER)
thereby triggering the release of Ca2+ into the cytoplasm. The increase in Ca2+ levels activates
cytoplasmic PKC which translocates to the membrane and is anchored to the plasma
membrane via DAG and phosphatidylserine (PS). Activated PKC isoforms phosphorylate
protein substrates in the membrane and cytosol to propagate signals throughout the cell that
culminate in various biological and cancer-related phenotypes.

Figure 1.1: Scheme of primary structures of protein kinase C family members showing domain
composition and activators. All PKC isoforms contain regulatory domains: (1) a pseudosubstrate
motif (green); (2) C1 domain (orange): C1A and C1B domains are the molecular sensors of phorbol
esters and diacylglycerol (DAG). But only cPKC and nPKC isoforms possess a C1 domain and are
responsive to DAG; (3) C2 domains (yellow): The cPKC C2 domain functions as calcium-binding
module. nPKC C2 domains do not bind calcium and aPKC isoforms do not contain a C2 domain; (4)
the kinase domain (blue) (Newton, 2001).

The PKC family transduces cell signals by promoting lipid hydrolysis (Nishizuka, 1995).
Many known membrane receptors transmit intracellular signals through activation of PKC
(Kenny et al., 2007; Lee and Bell, 1991). One known pathway for PKC activation is
described in Figure 1.2 (Koivunen et al., 2006). An external signal activates a G-ProteinCoupled Receptor (GPCR), which activates the GTPase enzyme phospholipase C (PLC).
PLC cleaves phosphoinositol-4,5-bisphosphate (PIP2) into DAG and inositol-1,4,53

trisphosphate (IP3). IP3 interacts with a calcium channel in the endoplasmic reticulum (ER)
thereby triggering the release of Ca2+ into the cytoplasm. The increase in Ca2+ levels activates
cytoplasmic PKC which translocates to the membrane and is anchored to the plasma
membrane via DAG and phosphatidylserine (PS). Activated PKC isoforms phosphorylate
protein substrates in the membrane and cytosol to propagate signals throughout the cell that
culminate in various biological and cancer-related phenotypes.

Figure 1.2: Activation of conventional PKC by an extracellular signal via G-coupled receptors.
PKC activation is initiated by an extracellular signaling molecule (e.g. EGF) that binds to a G-proteinlinked receptor (GPCR)/receptor tyrosine kinase (RTK) in the cell membrane. Next, the binding of the
signaling molecule triggers the activation of a heterotrimeric G-protein on the intracellular face of the
cell membrane. The G-protein activates phospholipase C (PLC) which cleaves phosphoinositol-4,5
bisphosphate (PIP2) into 1,2-diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3). Next, IP3
interacts with a calcium channel in the endoplasmic reticulum (ER) and causes release of Ca2+ into the
cytoplasm. The increase in Ca2+ levels activates PKC. Lastly, activated PKC phosphorylates its
specific substrates on serine/threonine residues (Koivunen et al., 2006).

1.2: Cancer Biology
Cancer consists of diseases in which abnormal cells divide without control, and remains the
second most common cause of death in the United States. In the last two decades, there have
4

been enormous studies in understanding the cellular and molecular basis of malignancy, its
initiation, promotion and progression.
In 2001, Hanahan and Weinberg described six key changes that occur in cancer which all
lead to enhanced tumor growth and survival: growth factor independence, evading growth
suppressors, avoiding apoptosis, maintaining replicative potential, angiogenesis and
invasion/metastasis (Hanahan and Weinberg, 2011). These phenotypes are developed in
different tumor types via distinct mechanisms and at various times during tumorigenesis. The
expansion of migration and invasive properties are key events in the oncogenic progression
of cells since they drive metastasis which is the most frequent cause of death for patients with
cancer. Metastasis is a multistep process in which cancer cells disseminate from the primary
tumor to distant organs (Figure 1.3) (Fidler, 2003). Greater knowledge of the mechanisms
that drive motility and invasion of these tumor cells is crucial to further understand metastasis
and to develop strategies to prevent it.

1.3: PKC and Cancer
PKC regulates multiple aspects of tumorigenesis, including cell proliferation, angiogenesis,
metastasis, and apoptosis, making it a major regulator in malignant transformation.
Early studies showing that PKC isoforms are activated by tumor-promoting phorbol esters
suggested an important role for PKC in carcinogenesis (Castagna et al., 1982; Niedel et al.,
1983). Activation of PKC leads to cell-type specific effects such as proliferation,
differentiation, apoptosis, migration and morphology. In different cancer types, PKC
isoforms have been shown to display different expression profiles and there is evidence of
isoforms having specific as well as overlapping roles during cancer progression. From the
three subclasses, PKC- andare among the most highly studied isoforms.
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Figure 1.3: The main steps in the formation of metastasis. (a) Cancer transformation and tumor
growth. (b) Proliferation and angiogenesis: the physiological process through which new blood
vessels form from pre-existing vessels. (c) Detachment and invasion: the cancer cells detach
themselves from the primary tumors and enter the bloodstream. (d) Circulation: the aberrant cells
travel via the blood stream. (e) Extravasation: the cells leave the blood stream and enter into the
surrounding tissues (Fidler, 2003).

Immunohistochemical studies have demonstrated over-expression of PKC- in prostate,
endometrial, high-grade urinary bladder and hepatocellular cancers (Koren et al. 2000;
Langzam et al. 2001; Koren et al. 2004; Varga et al. 2004). However, immunohistochemistry
of advanced stage human breast tumors revealed that in the majority of specimens PKC-
was down-regulated (Kerfoot et al. 2004). PKC- mediates anti-proliferative signaling and
plays a tumor-suppressing role in a number of cell types including intestinal, pancreatic, and
mammary cells (Detjen et al., 2000; Sun and Rotenberg, 1999). However, in other models,
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PKC- promotes proliferative and tumorigenic responses (Jiang et al. 2004; Sharma et al.
2007; Wu et al. 2008). Peltonen’s group showed that the PKC inhibitor Go6976 promotes
cellular junction formation and consequently inhibits invasion in cultured high grade urinary
bladder carcinoma cells (Koivunen et al., 2004). Previous studies in the Rotenberg lab
reported that over-expression of PKC- in non-transformed MCF-10A human breast cells
caused a pronounced increase in motility with loss of detectable E-cadherin, decreased
proliferation (due to slowed passage through G1 of the cell cycle) and radical alterations in
morphology (extensive and well-defined organization of actin stress fibers) (Sun and
Rotenberg, 1999).
Similar to the expression of PKC-, PKC-can be either up-regulated as in hepatocellular
cancer (Tsai et al., 2000) or down-regulated as in urinary bladder cancer (Langzam et al.,
2001). The most important function of PKC- is thought to be promotion of apoptosis. PKC activity is known to result in many pro-apoptotic signals and shows pro-apoptotic effects in
many cell lines, such as in UV-light-induced apoptosis of cultured breast cancer cells (Zeidan
et al., 2008). A recent study showed that PKC- has a pro-survival role by suppressing the
ERK1/2 pathway since depletion of PKC- in MDA-MB-231 human breast cancer cells was
sufficient to drive these cells into apoptosis (Lonne et al., 2009).
Similarly, both tumor-promoting and tumor-suppressing roles have been attributed to PKCDiaz-Meco’s group showed that PKC- deficient mice displayed an increase in Rasinduced lung carcinogenesis, suggesting a role for this kinase as a tumor suppressor in vivo
(Galvez et al., 2009). Another recent study showed that PKC-ζ inhibited colon cancer cell
growth and enhanced differentiation and apoptosis, while inhibiting the transformed
phenotype of these cells (Mustafi et al., 2006). For breast cancer development, PKC-ζ
activates the proliferative, invasive, and metastatic potential of breast cancer cells. Studies
7

demonstrated that PKC-ζ was required for human breast cancer cell chemotaxis (Liu et al.,
2009), and PKC- overexpression in MDA-MB-468 stimulated cell motility (Sun et al.,
2005). The stable overexpression of PKC- in immortalized mammary epithelial cells
(NMuMG) activated the mitogenic ERK pathway, leading to profound effects on the ability
of NMuMG cells to proliferate, adhere, migrate, and secrete proteases (Urtreger et al., 2005).
PKC isoforms apparently have overlapping, different, and even opposing biological functions
in the context of proliferation, transformation, and metastasis. There is a great degree of cell
type specificity which is likely due to the differential expression level of each PKC isoform
as well as varying ability to access intracellular compartments where protein substrates are
located.
The upstream or downstream components of PKC signaling pathways that determine its
functional effects in a specific context are not completely defined. In this project, we sought
to identify PKC substrates and to characterize how these substrates affect cancer-related
phenotypes in human breast cell lines.

1.4: PKC Substrates
The functions of PKC isoforms in cancer-related attributes result from their actions on
protein substrates in signaling pathways that support phenotypes such as motility, adhesion,
and proliferation. Identification of an intracellular substrate for each kinase could provide a
phospho-protein marker for detecting activity through a specific PKC-related signaling
pathway and also provide a novel target for drug discovery.
Evaluation of synthetic peptides as artificial substrates of PKC led to characterization of the
consensus phosphorylation motif K/R1-3(X)0-2S/T(X)0-2R/K1-3 (where X indicates any amino
acid) (Kemp and Pearson 1990; Pearson and Kemp 1991). The observation that a Ser/Thr
8

residue flanked by basic amino acids presents a good motif for PKC phosphorylation was
confirmed by the presence of this consensus sequence in many in vivo substrates. Moreover,
the combined use of motif identification and database search provides an effective strategy to
predict the likely substrates of a protein kinase.
Until now, very few known intracellular PKC substrates have undergone extensive
characterization for their functional significance; however, there are some PKC substrates
that were found related to cell motility and morphology. Some of these protein substrates are
listed below.
MARCKS: Myristoylated alanine-rich C-kinase substrate (MARCKS) is a filamenous (F)
actin crosslinking protein that has been implicated in membrane and cytoskeleton interactions
and plays important roles in cell shape, motility and transmembrane transport (Hartwig et al.,
1992; Herget et al., 1992, 1995; Blackshear, 1993; Taniguchi and Manenti, 1993). In mouse
melanoma cells, MARCKS with pseudo-phosphorylated mutations (Ser  Asp) at Ser-152,
Ser-156 and Ser-163 (the sites phosphorylated by PKC) resulted in its dissociation from the
plasma membrane and cytoskeleton and translocated into the cytosol. This event facilitated
the rearrangement of the actin cytoskeleton at the plasma membrane and promoted cell
migration (Chen and Rotenberg, 2010).
VASP: Vasodilator-stimulated phosphoprotein (VASP) is a member of the Ena-VASP protein
family which is involved in actin polymerization and interacts with other proteins involved in
cell motility. VASP is known to undergo phosphorylation at Ser-157 by PKC (Wentworth et
al., 2006). The phosphorylation of VASP plays an important role in remodeling of the actin
cytoskeleton in lamellipodia (membrane ruffling), filopodia (or focal adhesions), and stress
fiber formation.
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MAPs: Microtubule-associated proteins (MAPs) are proteins that interact with microtubules
of the cytoskeleton. Of particular interest is that MAP4 underwent phosphorylation at Ser815 by a bovine brain preparation of conventional PKC isoforms (Mori et al., 1991). Since
Ser-815 is directly involved in the binding between a microtubule and MAP4, its
phosphorylation by PKC inhibits the ability of MAP4 to promote microtubule assembly.
IQGAP: IQGAPs were initially identified as an effector for Cdc42 and Rac1 (Fukata et al.,
2002; Kuroda et al., 1999). IQGAPs inhibit the GTPase activity of Cdc42 and Rac1 by
stabilizing their GTP-bound form, and are consistent with their involvement in actindependent functions such as cell shape and motility (Bashour et al., 1997). IQGAP, as an
effector for Cdc42 and Rac1, was shown to be involved in the formation of cell–cell adhesion
sites through binding to E-cadherin and β-catenin (Kuroda et al. 1999; Noritake et al. 2004).
In addition, IQGAP proteins also participate in cancer cell invasion and metastasis. Their
expression was up-regulated in various invasive human cancers and the elevated levels of
IQGAP-1 were associated with a poor prognosis (Dong et al. 2006). Tandem mass
spectrometry analysis (MS/MS) and immunoprecipitation experiments revealed that Ser-1443
of IQGAP1 was phosphorylated in vivo, potentially by PKC-ε (Grohmanova et al., 2004).
However, IQGAP has not been further studied as a substrate of other PKC isoforms.

1.5: The Traceable Kinase Method
The Traceable Kinase Method initially developed by the Shokat laboratory offers an
approach to identify direct substrates of a protein kinase (Liu et al., 1998a). In this approach,
a protein kinase of interest is genetically engineered to accept a non-natural phosphate donor
substrate (A*TP) that cannot be bound by the corresponding wild-type protein kinase or other
protein kinases (Fig.4). Modification of the ATP binding active site entails site-directed
mutagenesis at a residue (typically methionine or isoleucine) that comes closest to the N610

amino group of the adenosine moiety of bound ATP. By replacing this residue with glycine
or alanine, more space is created so that a more “bulky” ATP analogue can be
accommodated. Consequently, the mutant kinase can accept a structurally modified ATP
analogue that is derivatize at the N6-amino group. Following transfer of the -phosphate,
direct substrates can be identified in a gel by autoradiography or by Western blot with an
antibody that recognizes the phosphorylated PKC consensus site. The strength of this
approach rests on the inability of the wildtype enzyme or any other protein kinase to bind the
ATP analogue, therefore reducing the level of background phosphorylation. It is important to
test the mutant kinase with several ATP analogues to determine which one best supports the
activity of the mutant while being minimally used by the wildtype enzyme.
This strategy was successfully applied to identify the direct substrates of several protein
kinases: v-Src (Liu et al., 1998a, 1998b), c-Jun N-terminal protein kinases (JNK) (Habelhah
et al., 2001) and CDK2 (Polson et al., 2001). In the first application of this method, the Shokat
group determined the first direct substrates of v-Src in fibroblasts (Shah and Shokat, 2002). In
that study, they determined from an X-ray crystal structure of v-Src co-crystallized with ATP
the appropriate residue (Ile-338) for mutagenesis due to its proximity to the N6-amino group
in ATP. Later, Abeyweera and Rotenberg applied the Traceable Kinase Method using an
ATP analogue ([-32P]-phenyl-N6-ATP) for characterization of 6-tubulin as a new PKC
substrate in MCF-10A cells with a traceable PKC- mutant (Figure 1.5) (Abeyweera and
Rotenberg, 2007). By aligning the ATP binding site of the PKC- sequence with that of
PKC- and PKC- to identify the appropriate sites for mutagenesis, Dr. Rotenberg’s group
also successfully developed and compared the phospho-protein profiles for PKC-, and PKC mutants, details of which are discussed in Chapter II (Chen et al., 2012).
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Figure 1.4: The Traceable Kinase Method. A protein kinase of interest is engineered to accept a
non-natural phosphate donor substrate (A*TP) that is poorly accepted by the wild-type protein kinase.
The active site is modified so that it can accommodate a structurally modified γ-32P-labeled nucleotide
A*TP. By comparing the autoradiograph with the Coomassie blue stained gel, radioactive bands are
excised from the gel for identification by MS/MS (Shah and Shokat, 2003).

1.6: The Small Rho GTPases –Rac, Cdc42, and Rho
The small Rho GTPases comprise a family of small signaling G proteins (20-30kDa), which
are members of the Ras superfamily. The most studied members are Rac1, Cdc42, and RhoA.
Rho GTPases have been described as “molecular switches” that play a role in actin dynamics,
cell proliferation, apoptosis, motility, gene expression and many other common cellular
functions. They cycle between an active GTP-bound state and an inactive GDP-bound state
(Figure 1.6) (Etienne-Manneville and Hall, 2002). In the GTP-bound form, they are able to
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interact with effector or target molecules to initiate downstream responses. Hydrolysis of the
GTP to GDP by GTPase activating protein (GAPs) drives these interactions while exchange
of GDP for GTP is catalyzed by guanine nucleotide exchange factors (GEFs) which
completes the cycle. Guanine nucleotide dissociation inhibitors (GDI) maintain small
GTPases in the inactive state.

Figure 1.5: Design of ATP binding site for mutants of PKC-. (A). Three-dimensional structure
of PKA with bound ATP in which the adenosine moiety is delineated by the translucent surface. (B).
Alignment of primary sequences in the vicinity of the ATP binding site for v-Src, PKA, and PKC-.
(C). In vitro phosphorylation of protein substrates co-immunoprecipitating with PKC- mutant
M417A (Abeyweera and Rotenberg, 2007).

Rac1, Cdc42 and RhoA play a vital role in cancer progression. All aspects of tumor
progression related cell migration, cellular polarity, cell adhesion, cytoskeletal reorganization, and their related signal transduction pathways are controlled through the
interplay between the Rho GTPases and their effectors. In Swiss 3T3 cells, constitutively
activated mutants of Rho were found to induce the assembly of focal adhesion and actin
stress fibers (Ridley and Hall, 1992). Rac1-regulated signal transduction pathway can
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stimulate actin polymerization to form actin-rich surface protrusions, notably lamellipodia
and membrane ruffles (Ridley et al., 1992). Microinjection of constitutively active Cdc42 into
Swiss 3T3 cells triggered the formation of actin-rich, finger-like membrane extensions
(filopodia) (Nobes and Hall, 1995). Rho GTPases also play an important role in the
establishment of functional cell-cell contacts (adherents junctions and tight junctions) and in
regulating the cell polarization. These facts reveal the important role of Rho GTPases in cell
migration (Figure 1.7).

Figure 1.6: The Rho GTPase cycle. The Rho GTPases cycle between an active GTP-bound state and
an inactive GDP-bound state. The cycle is highly regulated by three classes of protein: guanine
nucleotide exchange factors (GEFs) catalyze nucleotide exchange and mediate activation; GTPaseactivating proteins (GAPs) stimulate GTP hydrolysis, leading to inactivation; and guanine nucleotide
exchange inhibitors (GDIs) maintain the GTPase in an inactive state. In the GTP-bound form, they are
able to interact with effector or target molecules to initiate downstream responses (EtienneManneville and Hall, 2002).

The different Rho GTPase functions are regulated by their specific effectors that bind to the
activated Rho proteins through their GTPase binding motif such as the CRIB (Cdc42/Rac1
interactive binding) domain. To date, there are approximately 40 potential effectors of Rac1,
Rho and Cdc42 that were identified by using affinity chromatography and the yeast twohybrid system. For example, ROCK (Rho-associated coiled-coil-containing protein kinase)
that is an effector of Rho is required for the assembly of stress fibers and focal adhesions
(Ishizaki et al., 1997). WASP and PAK, as effectors of Cdc42, are involved in the formation
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of filopodia downstream of Cdc42 (Rohatgi et al., 1999; Zhao et al., 1998), whereas IQGAP1
and IQGAP2 are effectors for Rac1 and Cdc42 and function in actin polymerization
(Erickson et al., 1997).

Figure 1.7: The effect of Rho GTPases in different steps of cell migration. Rho GTPases play
important roles in lamellipodia or filopodia extension, formation of new adhesions, cell body
contraction, tail detachment and cell polarity (Ridley, 2001).

PKC-also is considered to be a downstream effector of Rho GTPases because PKC-
undergoes a protein-protein interaction with RhoA, Cdc42 and Rac1, and causes the
phosphorylation of downstream PKC- substrates (Flynn et al., 2000; Kamada et al., 1996;
Cook et al., 2006). There is some evidence showing that the downstream substrates of PKC
like MAP kinase and IQGAP are also effectors of Rho GTPases. In 1999, Dr. Rotenberg’s
group found that the overexpression of PKC- induced the formation of lamellipodia and
membrane ruffling and caused a dramatic increase in cell motility (Sun and Rotenberg,
1999). These PKC-–generated phenotypes were related to the function of Rac1 since the
dominant negative mutant of Rac1 impaired PKC-induce motility by 40% whereas the
dominant negative mutants of RhoA and Cdc42 were ineffective. A detailed mechanism

15

describing how Rho GTPases participate in PKC-induced malignant phenotypes has not yet
been addressed.
1.7: Cdc42 Effector Protein-4 (CEP4)
CEP4 (Cdc42 Effector Protein-4) or Borg4 (Binder of Rho GTPase-4) is a member of the
Cdc42-binding effector family. Rotenberg’s group demonstrated CEP4 is a PKC substrate in
MCF-10A cells (Chen et al., 2012). Initially named MSE55 (marrow stromal/endothelial cell
protein with a molecular mass of 55kDa), CEP1 was the first member of the family to be
characterized. A common motif found in the majority of Cdc42 and Rac effector proteins is
the conserved 16-aa CRIB motif, which serves as a binding site for Cdc42 and Rac. By
searching the GeneBankTM database for similarity with the CRIB domain, MSE55 was
identified to be a target protein for Cdc42 and Rac GTPase (Drechsel, 1995). In 1999,
MSE55 was reported to be a Cdc42 non-kinase effector protein that mediates actin
cytoskeleton reorganization at the plasma membrane in NIH 3T3 cells (Burbelo et al., 1999).
By performing a large two-hybrid screen of a whole mouse embryo library with TC10
GTPase as bait, Joberty et al. discovered a new family of Cdc42/TC10 binding proteins that
they called BORG (Binders Of Rho GTPases) proteins. One member of this family was
identical to the previously reported protein MSE55 and was named Borg5 (Burbelo et al.,
1999). Later, Dr. Burbelo’s group identified and sequenced three additional human Expressed
Sequence Tags (EST) cDNA clones that contained a CRIB domain and two additional
regions of amino acid homology to MSE55 by using the amino acid sequence of MSE55 to
query the EST database. These cDNA clones, designated CEP2, CEP3, and CEP4, encode
proteins of 210, 254, and 356 amino acids, respectively. Later, they also identified and
sequenced a mouse cDNA clone designated mCEP5, encoding a protein of 150 amino acids
that contains features in common with MSE55. They proposed that MSE55 was renamed as
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CEP1 to better describe its structural and functional relationship to other members of the CEP
family (Figure 1.8).
All CEP members contain the 16-amino acid CRIB consensus sequence which is required for
binding Cdc42. Following site-directed mutagenesis to create the triple alanine mutant CEP1D36A, P41A, H47A, it was found that these mutations eliminated the interaction of CEP1
with Cdc42, which single site mutations were insufficient to block binding. The CRIB triple
mutant also showed fewer cellular extensions and more stress fibers when compared with the
wildtype CEP1 in NIH 3T3 cell (Burbelo et al., 1999).
Genetically engineered overexpression of an individual CEP in fibroblast cells induced
pseudopodia formation. The CEP protein acted as a Cdc42 downstream effector, and
suggested a role in inducing actin filament assembly and cell shape changes. Moreover, in
keratinocytes, CEPs expression caused the loss of F-actin and reduced levels of E-cadherin at
adherent junctions, thereby suggesting that CEP interferes in the assembly of normal adherent
junctions (Hirsch et al., 2001). CEPs are also known to associate with septins and alter septin
organization to form long, thick septin filaments. GTP-Cdc42 negatively regulates septin
organization by binding to CEPs, thereby inhibiting their association with septins (Joberty et
al., 2001). Since 2001, there has not been any research on the CEP proteins. The molecular
functions and mechanisms of individual CEPs in mammalian cells therefore remain
unexplored.
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C

Figure 1.8: The CEP family of proteins. (A). Protein sequence alignments of the CEP proteins. (B).
Sequence alignment of CRIB, CI, and CII regions with other signalling molecules. (C). Polygenetic
tree (Hirsch et al., 2001).
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1.8: Outline of Thesis
In the work to be presented, the following subjects will be addressed: (1) In Chapter 3, in a
study that applied the Traceable Kinase Method (Chen et al., 2012), proteins that coimmunoprecipitate with traceable PKC-, -, and - are regarded as potential substrates of
these PKC isoforms in MCF-10A cells. From several potential PKC substrates, CEP4 was
identified as an intracellular PKC substrate; (2) In Chapter 4, phosphorylation site mutants of
CEP4 were constructed to determine the intracellular functional significance of its
phosphorylation at PKC consensus sites and to study the mechanistic significance of
phospho-CEP4 in cancer-related phenotypes in non-transformed MCF-10A cells; (3) In
Chapter 5, the dominant negative effect of the phosphorylation-resistant CEP4 mutant was
explored in malignant human breast cells; (4) In Chapter 6, the significance of this work is
discussed.
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Chapter 2: Materials and Methods

20

2.1 Materials
Human breast epithelial cells (MCF-10A cells) were obtained from The Barbara Ann
Karmanos Cancer Center and MDA-MB-231 cells (metastatic human breast cancer cells)
were from the ATCC (Manassas, VA). Competent DH5 cells, BL21competent cells, cell
culture media, antibiotics, serum, insulin, DABCO, DNA primers and secondary antibodies
(FITC-conjugated goat anti-rabbit and Alexa Fluor 594-conjugated goat anti-mouse) were
purchased from Life Technologies (Carlsbad, CA). The pCMV6-CEP4 construct was
purchased from Origene (Rockville, MD), pGL4.5 (Luc/CMV/Hygro) vector was from
Promega (Madison, WI), and the pGEX-2T-Cdc42-Q61L plasmid was obtained from
Addgene (Cambridge, MA). Quick-Change Mutagenesis kit was purchased from Agilent
Technologies, Inc. (Santa Clara, CA). OmicsLinkTM shRNA expression clones against PKC, - and - were purchased from GeneCopoeiaTM (Rockville, MD), and a HuSH-29 shRNA
expression vector targeting TEM4 (ARHGEF17) was obtained from Origene (Rockville,
MD). PolyExpress in vitro DNA transfection reagent was purchased from Excellgen, Inc.
(Gaithersburg, MD). Rabbit anti-CEP4 antibody was purchased from Bethyl Laboratory
(Montgomery, Texas) and anti-TEM4 was obtained from Novus Biologicals (Littleton, CO).
HRP-conjugated secondary antibodies and PARD6G primary antibody were acquired from
Santa Cruz Biotechnology (Santa Cruz, CA). Beta-actin, phospho-PKC substrate antibody,
Myc-tag mouse Ab and Myc-tag rabbit mAb were acquired from Cell Signaling Technology,
Inc. (Beverly, MA), and rabbit IQGAP monoclonal antibody was from Abcam (Cambridge,
MA). EZview red Anti-FLAG M2 affinity gel beads, protease inhibitor cocktail, and
phosphatase inhibitor cocktail were purchased from Sigma-Aldrich (St. Louis, MO). B-PER
bacterial protein extraction reagent, bacterial protease inhibitor cocktail, glutathione-agarose
and West Pico chemiluminescence reagents were purchased from Pierce Biotechnology
(Rockford, IL). Rac1 inhibitor, Cdc42/Rac1 GTPase inhibitor, and bis-indoleylmaleimide
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were obtained from Calbiochem-Millipore Corp. (Billerica, MA). The DAG-lactone reagent
(JH-131E-153) was a kind gift from Dr. V. Marquez (NCI-Frederick, NIH).
2.2

Plasmid Construction

2.2.1 Construction of Plasmids Encoding Pseudo-Phosphorylated or PhosphorylationResistant Mutants of CEP4
Substitution of serine residues by either an aspartate codon (pseudo-phosphorylated residue)
or alanine codon (phosphorylation-resistant residue) was carried out by the Quick-change
method. The single site mutants were made in the wild type construct pCMV6-CEP4 using a
commercially available site-directed mutagenesis kit (Agilent). For each mutant, two
mutagenesis primers (Invitrogen) were designed and synthesized according to the desired
mutation. The primers that were used to produce the pseudo-phosphorylated mutants at Ser18, Ser-77, Ser-80 and Ser-86 are given in the table below:
CEP4 pseudo-phosphorylated Mutants
CEP4 S18D
CEP4 S77D
CEP4 S80D
CEP4 S86D
CEP4 phosphorylation-resistant Mutants
CEP4 S18A
CEP4 S80A

CEP4 Mutants Primer:
5’ CAC-TCC-AAG-CGC-CGT-GAC-CGA-GCG-GAC-CTC-ACG 3’
5’ CGT-GAG-GTC-CGC-TCG-GTC-ACG-GCG-CTT-GGA-GTG 3’
5’ TCA-TCT-TCC-AAA-CGC-GAC-CTC-CTG-TCC-AGG-AAG 3’
5’CTT-CCT-GGA-CAG-GAG-GTC-GCG-TTT-GGA-AGA-TGA 3’
5’ AAA-CGC-AGT-CTC-CTG-GAC-AGG-AAG-TTC-CGG-GGC 3’
5’ GCC-CCG-GAA-CTT-CCT-GTC-CAG-GAG-ACT-GCG-TTT 3’
5’ AGG-AAG-TTC-CGG-GGC-GAC-AAG-CGG-TCA-CAG-TCG 3’
5’ CGA-CTG-TGA-CCG-CTT-GTC-GCC-CCG-GAA-CTT-CCT 3’
CEP4 Mutants Primer:
5’ CAC-TCC-AAG-CGC-CGT-GCC-CGA-GCG-GAC-CTC-ACG 3’
5’CGT-GAG-GTC-CGC-TCG-GGC-ACG-GCG-CTT-GGA-GTG 3’
5’ AAA-CGC-AGT-CTC-CTG-GCC-AGG-AAG-TTC-CGG-GGC 3’
5’ GCC-CCG-GAA-CTT-CCT--GGC-CAG-GAG-ACT-GCG-TTT 3’

Table 2.1: The single site mutation primers of CEP4 pseudo-phosphorylated and phosphorylation
resistant mutants.

2.2.2 Subcloning of Myc-tagged CEP4-WT/-18D80D/-18A80A into pCTAPA Vector for
Tandem Affinity Purification (TAP)
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The cDNAs for Myc-tagged WT-CEP4 and Myc-tagged mutants (~1.060 kb) were expressed
from a pCMV6 vector (4.929 kb) or a pCTAPA vector (4.5 kb), followed by purification and
digestion with BamHI and EcoRV. The digested products were purified on a 1% agarose gel
and eluted with Wizard SV gel clean up reagents. Each eluted cDNA insert (~1.060 kb) was
subcloned into BamHI/EcoRV sites of pCTAPA vector (~4.5 kb). All clones were verified by
DNA sequencing (Macrogen, Inc.). At least two clones for each constructs were selected and
expressed in MCF-10A cells. Following Western blot, CEP4 expression was demonstrated by
evidence of a 60kDa band using rabbit monoclonal anti-Myc diluted to 1:1000 (Cell
Signaling Technology, Inc.).

2.3

Transformation of Bacterial Cells and Plasmid Preparation

Competent DH5α cells were gently thawed on ice and 50 μl cells were transferred to a prechilled Eppendorf tube. Plasmid DNA was diluted to approximately 50 ng/μl. DNA (50ng)
was added to 50 μl cells and the mixture was incubated on ice. After 30 minutes, the
Eppendorf tube was subjected to 42oC heating for 45 seconds, and then placed on ice for 2
minutes to reduce the damage to DH5 cells. Pre-warmed (to 37oC) S.O.C medium (900 μl)
was added to the Eppendorf tube and incubated in a water bath shaker for 2 hours at 37oC.
The resulting culture (250 μl) was spread on an agar plate containing the appropriate
antibiotic. The plate was incubated in a 37oC incubator for over 16 hours. Single colonies
were picked and cultured for subsequent plasmid preparation. Plasmids were isolated from
DH5 by use of the Genopure Plasmid Midi-prep kit (Roche, Indianapolis, IN).

2.4

Cell Culture and Transfection

2.4.1 Cell Culture
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MCF-10A cells were cultured in 10-cm plates (BD Falcon) at 37oC and 5% CO2 in
DMEM:F12 media supplemented with 5% horse serum, insulin (10 g/ml), epidermal growth
factor (20 ng/ml), cholera toxin (100 ng/ml), and hydrocortisone (0.5 g/ml), and maintained
with antibiotics [2% penicillin/streptomycin, and fungizone (0.5 g/ml)]. MDA-MB-231 cells
were grown in high glucose with L-glutamine DMEM (ATCC) supplemented with 10% fetal
bovine serum, and antibiotics [1% penicillin/streptomycin, and fungizone (0.5 g/ml)]. Cells
were split once per week and washed with PBS. Cells were recovered from the plates by
trypsin-EDTA (0.25%) treatment and sub-cultured in a 1:3 ratio every 3–4 days. For
experiments in which cell lysates were prepared, cells were removed from the plates by
scraping.

2.4.2 Transient Transfection
Cells were re-plated one day prior to transfection so that the cell density was 70-80% on the
day of transfection. For 60-mm dishes, plasmid DNA (5g) was combined with PolyExpress
reagent (15 l) and incubated for 15 minutes at room temperature. The reagent/DNA (3:1)
mixture was added to the cells for 18-24 hours followed by replacement with fresh complete
medium. For cells transfected with PolyExpress, the transfection efficiency was typically
60%-80% at 48 hours post-transfection.

2.4.3 Stable Transfection of MDA-MB-231 Cell Line
MDA-MB-231 cells were cultured in DMEM containing L-glutamine (ATCC), 10% FBS,
0.2% fungizone, and 1% penicillin/streptomycin (Life Technologies, Inc.). Stable transfection
of MDA-MB-231 cells in complete medium was carried out using Lipofectamine
(Invitrogen) as transfection reagent. MDA-MB-231 cells were transfected with wildtype,
S18D-80D or S18A-80A mutants of a Myc-DDK tagged CEP4 cDNA construct (8 g) and
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Lipofectamine 2000 (Invitrogen, 12 μl for each well in a 6-well plate). At 48 hours posttransfection, the cell medium was replaced with selection medium containing 1000 μg/ml
G418 (50 mg/ml) for 4-5 days. Individual colonies from the transfected cells were isolated
after 3-4 weeks of a gradual reduction in the concentration of the selection drug to 600 μg/ml.
All stably transfected cell lines were maintained in growth medium containing G418 500
μg/ml. Cells were replaced with fresh media containing drug every 2 days. Protein expression
of Myc-tagged constructs in stable cells was verified by Western blot analysis using a rabbit
polyclonal anti-Myc antibody (1:1000, Cell Signaling Technology).

2.4.4 shRNA Transfection
Short hairpin RNA (shRNA) expression constructs specific for human PKC-α, PKC-δ, and
PKC-ζ and for the scrambled control shRNA reagent were from GeneCopoeia (Rockville,
MD). The shRNA-encoding plasmid (5 μg for a 60 mm plate) was transfected with
PolyExpress DNA transfection reagent in a ratio of 1:3 (μg shRNA/μl transfection reagent) in
serum-free medium. The reagent mixture was added to cells in 2.8 ml complete medium and
incubated with cells for 96h at 37oC (5% CO2). The bi-cistronic shRNA-encoding plasmid
co-expressed the shRNA product and the green fluorescent protein (GFP), thereby allowing a
determination of transfection efficiency. Protein knockdown was verified by Western blot
analysis.

2.5

In vitro Protein Kinase Activity Assay

Pure recombinant CEP4 (200 ng), PAK2 (300 ng), or CLASP (300 ng) were diluted in ice
cold 1X kinase buffer that contained 25 mM TRIS (pH 7,4), 10 mM MgCl2, 0.5 mM EGTA,
1 mM DTT, and 0.1 mg/mL phosphatidylserine with either 5 μM DAG-lactone (for PKC-α
and -δ) or 1 μM ceramide (for PKC-ζ). Each of the reactions was tested in vitro with pure,
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recombinant PKC-α (170 ng), PKC-δ (100 ng), or PKC-ζ (166 ng). In order to ensure that
PAK2 and CLASP1 were unphosphorylated prior to the kinase reaction, PAK2 and CLASP1
recombinant proteins were incubated with PP2A (25 M) for 2h at 30oC, followed by
addition of phosphatase inhibitors and incubation on ice for 30 minutes. The kinase reaction
was initiated by addition of ATP (100 μM final concentration) and the mixture was incubated
at 30°C for 30 min. The kinase reaction was quenched with 5X SDS sample buffer and
analysis of the phosphorylation reaction was conducted by Western blot with anti-PKC
substrate antibody (1:1000).

2.6

Cell Lysis and Western Blot

Cells were disrupted by sonication for 10 seconds for three times in the presence of lysis
buffer [50 mM TRIS (pH 7.4), 1 mM NaCl, 2 mM EGTA, 2 mM EGTA, 1% Triton X-100,
0.1% protease inhibitors and 1% phosphatase inhibitors], and centrifuged at 10,000 x g for 10
minutes to remove insoluble material. The protein concentration was determined with BioRad protein dye reagent. Samples of known protein concentration were denatured with 5X
SDS sample buffer [50% glycerol (v/v), 1% SDS, 0.05% bromophenol blue, 0.4 M Tris pH
6.8, and 2 mM dithiothreitol (DDT)], followed by heating at 95oC for 5 minutes. Proteins
were separated by SDS-PAGE, transferred to a PVDF membrane (Millipore Corp.), and
probed with the appropriate primary antibody. Immunoreactive bands were detected with
peroxidase-conjugated secondary antibody and detected by chemiluminescence (Pierce
Biotechnology, Rockford, IL).
2.7

Immunoprecipitation

2.7.1 Immunoprecipitation with CEP4 Antibody
MCF-10A cells were treated with DAG-lactone (10 μM) or DMSO (0.05 % v/v) for 60
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minutes at 37oC. The cells were harvested and dissociated by trypsinization followed by three
washes with 5 ml complete medium plus one wash with 5 ml serum-free medium. Cell
lysates were prepared by sonication 3x10 seconds in 500 l lysis buffer [50 mM TRIS (pH
7.4), 150 mM NaCl, 5 mM EGTA and 5 mM EDTA, 1% Triton X-100, 10 μM bisindoleylmaleimide, 0.1% protease inhibitors and 1% phosphatase inhibitors], followed by
centrifugation at 10,000 x g for 10 minutes. The supernatant was pre-cleared using 30 μl
protein A/G-agarose beads. The pre-cleared lysate was incubated with 2.5 μl CEP4 antibody
overnight at 4oC, followed by incubation of 50 μl protein A/G agarose beads for 1 hour. The
immuno-complex was obtained by centrifugation at 10,000 x g for 10 minutes and washed
three times in 500 l lysis buffer. The bound proteins were eluted with 1X SDS-PAGE
sample buffer by heating at 95oC for 5 minutes. Samples were resolved by SDS-PAGE
(typically 8%), transferred to a PVDF membrane, and immuno-reactive bands were detected
by the appropriate primary antibody.

2.7.2 Immunoprecipitation with EZview Red ANTI-FLAG M2 Affinity Beads
MCF-10A cells expressing CEP4 wildtype or its related mutants were harvested and
dissociated by trypsinization followed by three washes with 5 ml completed medium and one
wash with 5 ml serum-free medium. Cell lysates were prepared by sonication 3x10 seconds
in 500 l hypotonic, detergent-free lysis buffer [20 mM TRIS (pH 7.4), 2mM MgCl2, 2 mM
EGTA and 1 mM DTT, 10 μM bis-indoleylmaleimide, 0.1% protease inhibitors, and 1%
phosphatase inhibitors], followed by centrifugation at 10000 x g for 10 minutes. The
supernatant was pre-cleared using 30 μl mouse IgG-agarose beads. Sixty μl of EZview red
anti-FLAG M2 affinity beads (pre-equilibrated in cold TBS) were applied to the pre-cleared
lysate and incubated for 2 hours at 4oC. The immuno-complex was obtained by centrifugation
at 8200 x g for 5 minutes and washed three times in hypotonic, detergent-free lysis buffer.
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Bound proteins were eluted in 1X SDS-PAGE sample buffer and heating at 95oC for 5
minutes. Samples were resolved by 8% SDS-PAGE gel, transferred to a PVDF membrane,
and immuno-reactive bands were probed with the appropriate primary antibody.

2.8

Assay of Binding of CEP4 mutants to Cdc42

MCF-10A cells expressing Myc-tagged wildtype CEP4, S18D-80D-CEP4, or S18A-S80ACEP4 were lysed in 500 l hypotonic, detergent-free lysis buffer [20 mM TRIS (pH 7.4),
2mM MgCl2, 2 mM EGTA and 1 mM DTT, 10 μM bis-indoleylmaleimide, 0.1% protease
inhibitors, and 1% phosphatase inhibitors], followed by centrifugation at 10,000 x g for 10
minutes. The supernatant was pre-cleared using 30 μl mouse IgG-agarose beads. Sixty μl of
EZview red anti-FLAG M2 affinity beads (pre-equilibrated in cold TBS) were applied to the
pre-cleared lysate and incubated for 2 hours at 4oC. The immuno-complex was obtained by
centrifugation at 8200 x g for 5 minutes and washed three times in hypotonic, detergent-free
lysis buffer. The bound proteins were eluted by 1X SDS-PAGE sample buffer by heating at
95oC for 5 min. Samples were resolved by 8% SDS-PAGE gel, transferred to a PVDF
membrane, and immuno-reactive bands were probed with the appropriate primary antibody.
BL21 bacterial cells containing plasmids encoding glutathione S-transferase (GST)-tagged
Cdc42-Q61L were cultured to a density of A600 = 0.6~1.0. Expression of the fusion protein
was induced by adding isopropyl-βD-thiogalactoside to a final concentration of 0.1 mM and
the cells were cultured for an additional 3–5 hours (or overnight) at 37°C. To extract the
protein from bacterial cells, the cells were collected by centrifugation at 5000 x g for 10
minutes, and the pellets were suspended with 3 ml of B-PER lysis reagent containing 0.2% (6
μl) lysozyme, 0.2% (6 μl) DNase I and 1% (30 μl) halt protease inhibitor. To separate soluble
proteins from insoluble material, the resulting lysate was centrifuged at 15000 x g for 5
minutes. The supernatant was incubated with 500 μl glutathione-Sepharose affinity resin in a
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Bio-Rad mini-column pre-equilibrated in wash buffer (50 mM Tris, 150 mM NaCl, pH 8.0),
and the column was washed twice with 10 resin bed volumes of wash buffer. The beads with
immobilized GST-Cdc42-Q61L were suspended in wash buffer and transferred to an
Eppendorf tube, centrifuged at 8000 x g for 5 minutes, and the buffer was removed. The precleared MCF-10A cell lysate (described above) was incubated with immobilized GSTCdc42-Q61L by rotation at 4oC for 40 minutes. After two washes with hypotonic, detergentfree lysis buffer, the bound protein was eluted by boiling with 1X SDS-PAGE sample buffer,
resolved by 8% SDS-PAGE, and transferred to a PVDF membrane. Anti-myc rabbit mAb
was used to determine the amount of myc-tagged CEP4 that had bound to Cdc42.

Figure 2.1: Photomicrographs of human breast epithelial cells during the cell
sedimentation method. Bright field micrographs were recorded with a phase contrast
microscope (A, B), and with a fluorescence microscope (C, D) to visualize GFP-expressing
cells. Images shown in A and C were captured immediately after the manifold had been
removed (t=0), and images shown in B and D are images of the cells shown in A and C
captured 6 hours later. The area of each circle was measured with Motic Image software.
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2.9

Motility Assay

The extent of cell movement was evaluated by the cell sedimentation method (CSM Inc.).
This assay was carried out with a 10-well glass slide and a 10-hole manifold. The cells
(~8x103) were applied in 1 l to the slide through one of the holes of the manifold so that the
cells sedimented as a tight concentric circle in the corresponding well. After incubation
overnight at 37oC (5% CO2), the manifold was removed and the cells were detected under a
Nikon Diaphot microscope (Moticam 2000) at t = 0 and t = 6 hours. To study the effect on
motility of a drug (DAG-lactone, Cdc42 inhibitor, or Rac inhibitor), the medium was
replaced at t=0 with fresh medium containing the specific reagent. The extent of movement
was determined by measuring the change in total area over 6 hours using Motic Image
software. Each experiment was performed in triplicate and averaged. Three independent
experiments were performed.

2.10 Proliferation Assay

Cell proliferation was measured by using Alamar Blue (Life Technologies) in a fluorescencebased assay that can be used to assess survival and proliferation of mammalian cells. Cells
were added to a 96-well plate at a density of 1x103 cells/l complete medium and incubated
at 37°C in a 5% CO2 atmosphere overnight to allow attachment. On day 2, Alamar blue was
added to each well to a final concentration of 4% v/v (7.2μl /180μl). Wells containing 180 μl
growth medium without any cells served as the blank. After incubation for 3 hours, the
fluorescence of each well was measured using a plate reader (SpectraMax M5 Microplate
Reader) set at λex = 530 nm and λem = 590 nm and a gain of 40. The plate was returned to the
incubator until the next time point.

2.11 Immunocytochemistry
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2.11.1 F-actin Staining
For F-actin experiments, MCF-10A cells were cultured overnight on poly-lysine-coated
coverslips and transfected with the Myc-tagged CEP4 vector control or one of the CEP4
double mutant constructs (S18D-S80D, S18A-S80A). Forty-eight hours post-transfection,
each coverslip was washed twice in 2 ml PHEM buffer (60 mM PIPES, 25 mM HEPES, 10
mM EGTA and 2 mM MgCl2, pH 6.9). The cells were fixed for 15 minutes with 3.7%
paraformaldehyde in 0.1 M PBS (pH 7.4). Non-specific sites were blocked for 15 minutes at
37oC with immuno-blocker (0.1% sodium azide and 2% BSA in TBST). After blocking, the
cells were incubated 1.5 hours at 37oC with Myc-tagged rabbit mAb diluted to 1:300 (Cell
Signaling Technology), followed by FITC-conjugated goat anti-rabbit secondary antibody
diluted to 1:300 (Santa Cruz Biotechnology). F-actin was stained with rhodamine-phalloidin
diluted to 1:300 (Cytoskeleton) for 1 hour at 37oC and nuclei were stained with Hoechst
33342 stain diluted to 1:1000 (Invitrogen) for 5 minutes at 37oC before mounting. Imaging
was performed with a Plan-Neofluor 63X oil immersion objective lens on a Zeiss Axio
Imager-M2 upright fluorescence microscope.

2.11.2 IQGAP and E-cadherin Staining
MCF-10A cells transfected with the myc-tagged CEP4 vector control or one of the CEP4
mutant constructs were analyzed for localization and expression of IQGAP or E-cadherin.
Forty-eight hours post-transfection, each coverslip was washed twice in 2 ml PBS and the
cells were fixed for 10 minutes with 4% PFA in 0.1 M PBS (pH 7.4). Depending on the
purpose of the experiment, cells were stained with mouse/rabbit monoclonal anti-Myc diluted
to 1:300 (Cell Signaling Technologies), rabbit monoclonal anti-IQGAP diluted to 1:200
(Abcam), or mouse monoclonal anti-E-cadherin diluted to 1:150 overnight (Santa Cruz
Biotechnology), followed by either FITC-conjugated goat anti-rabbit (green, 1:300) or Alexa
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Fluor 594-conjugated goat anti-mouse secondary antibodies (red, 1:300). Cells were mounted
on clean glass slides with DABCO and sealed. Images were acquired by a 63x1.4NA or a
100X oil immersion objective lens using the Axio Imager-M2 upright fluorescence
microscope (Zeiss).

2.12 Tandem Affinity Purification (TAP) Method
CEP4-associated proteins were isolated by using tandem affinity purification (TAP) by
following the Inter-Play Mammalian TAP System protocol (Agilent Technologies). The TAP
method entailed purification of a protein complex under non-detergent conditions by two
consecutive affinity columns (streptavidin and calmodulin affinity resins). The resulting elute
was detected on a Gelcode Blue-stained SDS-PAGE gel, and selected protein bands were
analyzed by mass spectrometry. MCF-10A cells were transfected with the TAP empty vector,
TAP-CEP4-S18A/S80A, or TAP-CEP4-S18D/S80D. After 48 hours, cells were suspended in
1 ml lysis buffer containing 1% of protease inhibitor and 1% of phosphatase inhibitor, and
lysed by three successive rounds of freezing the cells at -150°C for 10 minutes, followed by
thawing in cold water for 10 minutes. After removal of cell debris by centrifugation at 16,000
x g for 10 minutes, the crude cell lysates were incubated with 100 μl streptavidin resin (preequilibrated with streptavidin binding buffer) for 2 hours at 4°C. The resin containing bound
protein was washed twice with 750 μl streptavidin binding buffer and the proteins were
eluted with 200 μl streptavidin elution buffer by incubating with rotation for 1 hour at 4oC.
The elutes were applied to 50 μl calmodulin resin (pre-equilibrated with calmodulin binding
buffer) at 4°C for 3 hours and washed twice with 750 μl calmodulin binding buffer. The
bound proteins were eluted by boiling with 1X SDS-PAGE loading buffer at 95°C for 5
minutes, and resolved by 8% SDS-PAGE. The identities of eluted proteins were revealed by
mass spectrometry analysis of selected bands that appeared with the S18D/S80D-CEP4
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mutant but not with the S18A/S80A-CEP4 mutant. The gel was stained with Gelcode Blue
(Pierce), and bands of interest were excised for identification by mass spectrometry.

2.13 Pull-Down Assay of Activated Small GTPases
Activation of small GTPases was measured in lysates of MCF-10A cells using commercially
available buffers (Cytoskeleton, Inc.). Briefly, cells (transfected with either CEP4 18D/80D
or CEP4 18A/80A) were disrupted in a lysis buffer (50 mM TRIS, pH 7.5, 10 mM MgCl2,
0.5 M NaCl, 2% Igepal) supplemented with phosphatase and protease inhibitors followed by
centrifugation at 13,000 x g at 4 °C for 10 min. Agarose beads conjugated to either PAKbinding domain (PBD) (Millipore Corp.) or Rho-binding domain (RBD) (Cytoskeleton, Inc.)
were used in a pull-down assay to isolate activated G-proteins. Cell lysates with a total
protein content of 600 g of protein were incubated with PAK-PBD beads (10 g) or RBD
(25 g) beads at 4°C for 1h. The beads were washed once with wash buffer (25 mM TRIS,
pH 7.5, 30 mM MgCl2 and 40 mM NaCl) followed by centrifugation at 4°C. The entire
sample was loaded and bound proteins were separated by 12% SDS-PAGE and
immunoblotted with anti-Rac or anti-Cdc42 (Cell Signaling Technology), or anti-RhoA
(Cytoskeleton, Inc.).

2.14 Mass Spectrometry
Identification of proteins was performed at the Keck Foundation Mass Spectrometry
Resource Laboratory at the Yale University Medical Center. Gel-resolved bands were excised
and proteins were digested in situ with trypsin. The resulting peptides were analyzed by LC−
MS/MS on a LTQ Orbitrap mass spectrometer. All MS/MS spectra were searched against the
NCBI database with a probability or significance threshold of p < 0.05 using the automated
MASCOT algorithm. Identification required that two or more MS/MS spectra matched those
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of the same protein entry in the database, and that matched peptides corresponded to tryptic
peptides in the protein.

2.15 Statistical Analysis
Each experiment was performed a minimum of three times. Changes in area for cell
migration measurements between groups were assessed with Student’s t test. Data are
expressed as mean ±standard deviation.
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Chapter 3: Identification of Novel Substrates of
Protein Kinase C Isoforms in Human Breast Cells
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3.1: Introduction
PKC was first identified more than three decades ago as a calcium- and phospholipiddependent serine/threonine-specific protein kinase. Since its discovery, PKC has been studied
and recognized as a major player in a wide variety of cellular processes, and has become
increasingly attractive for oncology research (Tsai et al., 2000; Teicher, 2006; Martiny-Baron
and Fabbro, 2007; Urtreger et al., 2012).
The discovery of PKC as a major intracellular receptor for tumor promoting phorbol esters
suggested the importance of PKCs in tumor initiation and progression (Castagna et al., 1982;
Niedel et al., 1983). Over-expression or down-regulation of PKC isoforms have been
described in different types of cancer or at different stages of tumor development, which
makes it difficult to assign a particular role for individual PKC isoforms in cancer. This
complexity suggests that PKC isoforms have specific as well as overlapping roles during
cancer progression. In previous studies conducted by the Rotenberg lab, over-expression of
wildtype PKC- in non-transformed, non-motile human breast MCF-10A cells led to
suppressed cell proliferation, dramatically increased cell motility, and radical alternations in
cell morphology (large, disaggregated, and flat, with formation lamellipodia, membrane
ruffling and extensive actin fibers) (Sun and Rotenberg, 1999). In human breast cells, PKCis known to promote migration (like PKC-) or survival (unlike PKC-), as well as other
aspects of the malignant phenotype (Kiley et al., 1999; Lønne et al., 2009; Mccracken et al.,
2003). In contrast, some recent studies has shown that PKC-is considered to be a novel
tumor suppressor (Galvez et al., 2009; Nazarenko et al., 2010). In NMuMg human breast
cells, PKC-apparently operated through different signaling pathways because stable
overexpression of PKC-showed higher clonogenic ability and protease secretion and a
significantly lower migration rate (Urtreger et al., 2005).
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The role of PKC isoforms in cancer progression results from phosphorylation of substrates
lying on signaling pathways that govern cancer-related phenotypes. However, each isoform
may interact with its unique substrates or may share substrates with other PKC isoforms.
Identification of an intracellular substrate for which a functional significance can be
established would provide a phospho-protein marker for detecting activity through a PKCrelated signaling pathway and a novel target for drug discovery. At present, very few
intracellular protein substrates have been identified that have functional significance. The
identification and characterization of novel PKC isoform-specific intracellular substrates has
great importance for understanding the mechanisms about how each PKC isoform affects cell
behavior and its specific role in cancer progression.
In this study, PKC-, -, and - were selected for analysis since they are representative of
conventional, novel, and atypical subclasses of PKC, respectively. Knowledge of their
substrates and whether they are shared or specifically selected by a single isoform, would
clarify whether isoform-specific mechanisms are operating, and thereby inform strategies for
the design of anti-cancer drugs. We applied the traceable kinase method to identify novel
substrates of PKC-, -, and - in human breast cells. Because the over-expression of PKC induced motility and formation of lamellipodia and membrane ruffling in non-transformed
MCF-10A cells (Sun and Rotenberg, 1999), these phenotypes suggested the participation of
specific small GTPases (Ridley and Hall, 1992; Nobes and Hall, 1995; Schmitz et al., 2000).
Based on these previous findings, PKC isoforms may interact with GTPase-related effector
and regulatory proteins.
The Rotenberg lab applied the Traceable Kinase Method using an ATP analogue ([-32P]phenyl-N6-ATP) to identify substrates of a traceable PKC- mutant (Abeyweera and
Rotenberg, 2007). Expression of this mutant in MCF-10A cells led to the identification by
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MS/MS of several potential substrates in MCF-10A human breast cells. Most recently, the
Rotenberg lab developed a traceable mutant for each of three PKC isoforms (- and -)
and analyzed their phospho-protein profiles in parallel. The high affinity substrates were
isolated by co-immunoprecipitation of the traceable PKC isoform mutants or wild type using
anti-FLAG (for PKC-/-) or anti-PKC- (for PKC-containing a short -tag). Those
substrates that co-immunoprecipitated with the traceable kinase mutants and underwent
phosphorylation following addition of the ATP analogue N6-phenyl-ATP (but minimally by
the wildtype enzyme) were detected by Western blot using the PKC substrates antibody. This
antibody specifically detects the phosphorylated PKC consensus site and the phospho-protein
profile for each traceable PKC, shown in Figure 3.1. Selected bands were excised from a
companion SDS-PAGE gel containing the same samples run in parallel, and the proteins
contained in those bands were identified by mass spectrometry.
The MS/MS results are listed in Table 3.1A which details many of the identified proteins,
such as the small G-proteins and their accessory proteins that were judged to be related to
cancer-related phenotypes. Some proteins were already known to be PKC substrates such as
IQGAP (Grohmanova et al., 2004), MAP4 (Mori et al., 1991) and VASP (Wentworth et al.,
2006) (Table 3.1B). Other proteins were considered as novel candidate substrates like
ROCK1/2, CEP4, PAK2 and CLASP. In this Chapter, the objective was to determine which
of these novel candidates function as PKC substrates in MCF-10A cells.
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Figure 3.1: Phosphoprotein profiles of WT and traceable PKC isoforms. MCF-10A transfectants
expressing epitope-tagged WT or a traceable mutant of each PKC isoform were lysed in detergentfree medium, and each isoform was immunoprecipitated, as described in Materials and Methods. This
step facilitated the isolation of high-affinity substrates of each PKC isoform. Following the addition of
N6-phenyl-ATP to each immunoprecipitated enzyme under activating conditions (phosphatidylserine
for PKC- and - and ceramide for PKC-), phosphorylated products were resolved via SDS−PAGE
and stained with Gelcode Blue. Western blot analysis of an aliquot of each sample (representing 25%
of the total sample) was conducted with a duplicate gel, and the resulting blot was probed with PKC
substrate antibody (1:1000). Each WT−traceable mutant pair was aligned with the corresponding
Gelcode blue-stained gel that serves as the loading control. Bands excised for MS/MS analysis are
indicated with a caret (<). Each phospho-protein profile is representative of three independent
experiments (Chen et al., 2012).
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Table 3.1: Proteins that co-immunoprecipitate with traceable PKC isoforms. A. Proteins were
identified by MS/MS, as described in the Materials and Methods. The Mascot protein score is
indicated next to each detected protein. Those proteins that contain one or more potential PKC
phosphorylation sites at either partial or full consensus sequences are shown in bold. B. Proteins
identified by MS/MS that had been previously identified as either a substrate or binding protein of
PKC are shown along with the site of PKC phosphorylation (given in parentheses) (Chen et al., 2012).

3.2: Results
Based on the list of proteins identified by MS/MS, the possible PKC candidate substrates
were narrowed down to four proteins: CEP4 (43 kDa), PAK2 (63 kDa), CLASP1 (170 kDa)
and ROCK-1 (200 kDa) which co-immunoprecipated with either PKC- or PKC- These
four proteins were selected for the following reasons: first, the primary structures of these
proteins contain at least one partial or complete consensus site for phosphorylation by PKC;
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second, they are all related to small Rho GTPases and are known to play a functional role in
cell morphology and cell motility.
ROCK is a major downstream effector of small GTPase RhoA. ROCK is involved in cell
morphology and cell migration by regulating actin organization (Riento and Ridley, 2003).
The Cdc42 Effector Protein-4 (CEP4)/Borg4 is a member of the Cdc42-binding protein
family. CEP4 induces pseudopodia formation by acting as a Cdc42 effector, which suggests a
role in inducing actin filament assembly and cell shape changes (Joberty et al., 1999; Burbelo
et al., 1999; Hirsch et al., 2001). P21-activated protein kinase (PAK) is activated by Rac1 and
Cdc42 and is therefore an effector of these GTPases. PAK is known to be involved in
numerous biological functions, including cytoskeletal organization, cell motility, cell growth
and apoptosis (Bokoch, 1998; Coniglio et al., 2008; Siu et al., 2010). CLASP1 (CLIPassociating protein) is a microtubule (MT) plus-end binding protein that associates with
CLIP-170 and CLIP-115 (cytoplasmic linker proteins) (Galjart, 2005). CLASPs can induce
local stabilization of MTs and regulate MTs dynamics in polarized cells in response to
signaling cues (Lansbergen et al., 2006; Watanabe et al., 2009).
An investigation of ROCK1 demonstrated that ROCK1 is not a PKC substrate. This
conclusion was based on the absence of phosphorylation of ROCK1 by a pure, recombinant
PKC isoform (-, or -) in vitro, and by the absence of phosphorylation in MCF-10A
cells following DAG-lactone treatment (Figure 3.2) (Chen, X. Ph.D. Thesis, 2010).
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Figure 3.2: In vitro and intracellular kinase assay with ROCK. (Chen, X. Ph.D. Thesis, 2010)

Figure 3.3: In vitro kinase assay of CEP4, PAK2 or CLASP-1. Pure recombinant CEP4 (700 ng),
CLASP (1 g) and PAK2 (300 μg for the whole cell lysate) were analyzed for phosphorylation by
individual PKC isoforms in vitro. Each protein was tested in vitro with pure, recombinant PKC-α (170
ng), PKC-δ (100 ng), or PKC-ζ (166 ng). In order to ensure that CLASP1 was dephosphorylated prior
to performing the kinase reaction, it was treated with PP2A for 2h at 30oC, following which
phosphatase inhibitors were added and the protein was kept on ice for 30 min. The reaction was
conducted in 1X kinase buffer, which contained 0.1 mg/mL phosphatidylserine with either 5 μM
DAG-lactone (for PKC-α and -δ) or 1 μM ceramide (for PKC-ζ). The reaction was initiated by the
addition of 100 μM ATP and incubated at 30°C. After 30 min, each reaction was quenched with
sample buffer and the analysis of phosphorylation was conducted by Western blotting with anti-PKC
substrate antibody (1:1000).
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Figure 3.4: Testing of phosphorylation of potential PKC substrates in MCF-10A cells. Cells
were treated with DAG-lactone (10 μM) or DMSO (0.05%, v/v) for 1 hour at 37oC. The cells were
harvested and dissociated by trypsinization followed by three washes with 5 ml complete medium and
one wash with 5 ml serum-free medium. Cell lysates were prepared by sonication 3x10 seconds in
lysis buffer [50mM TRIS (pH 7.4), 150 mM NaCl, 5 mM EGTA and 5 mM EDTA, 1% Triton X-100,
10 μM bis-indoleylmaleimide, 0.1% protease inhibitor cocktail, and 1% phosphatase inhibitor
cocktail], followed by centrifugation at 10000 x g for 10 minutes. The supernatant was pre-cleared
using 30 μl protein A/G- agarose beads for 1 h. The pre-cleared lysate was aliquotted into three
Eppendorf tubes (200 ng/tube), followed by incubation with 5 μl anti-CEP4 antibody (Bethyl Labs), 5
μl anti-PAK2 antibody (Cell Signaling Technology), or 5 μl anti-CLASP1 antibody (Epitomics)
overnight at 4oC. The immunocomplexes were collected by incubation of 50 μl protein A/G-agarose
beads for 1 hour at 4oC and centrifugation at 10000 x g for 10 minutes. The pellets were analyzed by
Western blot with the PKC substrates antibody (1:1500) that recognizes the phosphorylated PKC
substrate consensus site in phospho-CEP4, or CEP4 antibody (1:2000) to establish equivalent protein
loading.
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3.2.1 Testing of Phosphorylation of Potential PKC Substrates in Vitro
To determine if CEP4, PAK2 or CLASP1 are PKC substrates in vitro, the pure recombinant
protein of each was obtained and evenly divided into different kinase reactions and subjected
to phosphorylation with PKC-, -or - in the presence of ATP and the appropriate
activator. Phosphorylated products were detected by Western blot with the PKC substrate
antibody. CEP4 and CLASP1 recombinant proteins were purchased from Novus Biologicals
(Littleton, CO). PAK2 protein was obtained by immunoprecipitation from MCF-10A cells
using PAK2 antibody. In Figure 3.3, CEP4 and PAK2 each underwent phosphorylation by
PKC-, and - in vitro; in addition CEP4 was a substrate for -in vitro. However, CLASP1
was shown to be phosphorylated even without addition of a protein kinase. In order to ensure
that the recombinant protein CLASP1 was unphosphorylated, we treated CLASP1 with
protein phosphatase 2A (PP2A) prior to the kinase reaction. However, the result was not
improved (Figure. 3.3).

3.2.2 Testing of Phosphorylation of Potential PKC Substrates in MCF-10A Cells
To confirm the validity of the in vitro results, intracellular phosphorylation state of each
potential substrate was analyzed following its immunoprecipitation from MCF-10A cells
treated with or without DAG-lactone. The MCF-10A cell line is a non-tumorigenic, nontransformed human mammary epithelial cell line. These cells express low levels of PKC-
and offer a low background of substrate phosphorylation. DAG-lactone, an activator of
conventional and novel PKC isoforms, activates conventional and novel PKC isoforms in
MCF-10A cells, and thereby promotes the phosphorylation of PKC substrates.

MCF-10A cells were first treated with DAG-lactone (10 M) for 30 min or DMSO as the
vehicle control. Following the preparation of lysates, the endogenous protein was
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immunoprecipitated with an antibody corresponding to CEP4, PAK2, or CLASP-1, and the
pellet was analyzed by western blot using the phospho-(Ser) PKC substrate antibody and a
protein-specific antibody that detects the total level of expression of the protein being tested.
Of these proteins, only CEP4 showed strong phosphorylation in response to DAG-lactone in
MCF-10A cells (Figure 3.4A). In contrast, PAK2 and CLASP1 showed undetectable
phosphorylation in MCF-10A cells after stimulation by DAG-lactone (Figure 3.4 B, C).
Based on the result from the in vitro and intracellular kinase assays, it was concluded that
CEP4 is a PKC substrate in MCF-10A cells.

3.2.3 Stoichiometry of Phosphorylation of Intracellular CEP4 Relative to the Total
CEP4
After confirming that CEP4 undergoes phosphorylation in MCF-10A cells in response to
DAG-lactone, we sought to quantitate the ratio of phospho-CEP4/total CEP4 in unstimulated
and stimulated cells in order to establish the number of PKC phosphorylation sites. The ratio
of intracellular phospho-CEP4 relative to total CEP4 was determined by reference to known
amounts of the pure, recombinant CEP4 protein standard that had been phosphorylated by
pure, recombinant PKC- in vitro. A time course of in vitro phosphorylation demonstrated
that maximal phosphorylation of pure, recombinant CEP4 was achieved after 2 hours at 30 oC
(Figure 3.5A). The phosphorylated product was subsequently used as a standard for
quantitating the phosphorylation of intracellular CEP4. The experiment consisted of a
Western blot containing known picomole (pmole) amounts of standard phospho-CEP4 run in
the gel with samples of immunoprecipitated CEP4 from MCF-10A cells that had been treated
for 1 hour with DAG-lactone (10 M). For comparison with the total amount of CEP4, a
duplicate blot was performed with identical samples and known amounts of pure,
recombinant unphosphorylated CEP4. Each blot was probed with either the PKC substrates
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antibody or CEP4 antibody to detect phospho-CEP4 or total CEP4 protein, respectively.
Quantitation of phospho-CEP4 or total CEP4 triplicate samples was performed with ImageJ
by comparing the samples with known amounts of standard CEP4 or phospho-CEP4 protein
present in the same blot (Figure. 3.5B). The ratio of phospho-CEP4 to total CEP4 in DAGlactone-treated cells was calculated to be 3.2 ± 0.5 pmol, the average of two independent
experiments (each consisting of triplicate measurements). This finding implies that in
response to DAG-lactone, PKC isoforms phosphorylate an average of three to four sites in
CEP4.

3.2.4 Interference of Intracellular CEP4 Phosphorylation by shRNA-Encoding
Plasmids of PKC Isoforms
To evaluate whether CEP4 serves as an intracellular substrate for one or more PKC isoforms,
MCF-10A cells were transfected with individual shRNA-encoding plasmids for isoform  or -, and their interference in CEP4 phosphorylation was evaluated under conditions
of DAG-lactone stimulation. Each shRNA-encoding plasmid featured co-expression of GFP
so that the transfection efficiency could be readily determined. Following a 48-hour
incubation period, the transfection efficiency was found to be >70%. However, a period of 96
hours was required to produce maximal knockdown of each PKC isoform. The single
plasmids used for PKC- and - had been validated by the manufacturer for their ability to
knockdown their intended target and were effective at knocking down expression of an
isoform by 60−100% in MCF-10A cells (Figure 3.6A). Of four constructs obtained for PKC, two (-2 and -3) were effective in achieving knockdown of PKC- (by 80−90%) in MCF10A cells (Figure 3.6A). In Figure 3.6C, it was confirmed that the PKC- shRNA (-2 and 3) successfully knocked down the expression of PKC-and had no effect on PKC- and-
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Figure 3.5: Stoichiometry of intracellular phospho-CEP4 to total CEP4 in unstimulated and
stimulated cells. Phosphorylation of pure, recombinant CEP4 (1 mg) was conducted with pure,
recombinant PKC- (0.74 mg) (Sigma-Aldrich), as shown in panel A, and was complete after 2 hours.
Each time point consisted of 200 ng (4 pmol) of CEP4 protein. (B) Intracellular phosphorylation of
CEP4 was tested in MCF-10A cells cultured in 60 mm plates and treated for 1 hour with 10 μM
DAG-lactone or DMSO (0.1%, v/v) as the vehicle control. Whole cell lysates were prepared in 0.5 ml
of 50 mM TRIS-HCl, 150 mM NaCl, 5 mM EGTA, 5 mM EDTA, 1% Triton X-100, 10 M bisindoleylmaleimide, phosphatase inhibitors, and protease inhibitors. Lysates were pre-cleared with a
1:1 combination of rabbit IgG-agarose and protein A/G-agarose, and CEP4 protein was
immunoprecipitated with 3 g CEP4 antibody and protein A/G-agarose. Western blotting of the
immunopellets was used to assess CEP4 phosphorylation with the PKC substrate antibody (1:1500).
To demonstrate equivalent protein loading and to determine the total amount of CEP4 protein in each
sample, a duplicate blot was probed with anti-CEP4 (1:2000). The results are representative of two
independent experiments. The ratio of intracellular phospho-CEP4 relative to total CEP4 in each
sample was determined with ImageJ and by reference to the known standards for phospho-CEP4 or
CEP4. Standard phospho-CEP4 that was produced after 2 hours by pure, recombinant PKC- in panel
B and represents the maximally phosphorylated protein.

In DAG-lactone-treated cells, silencing of each individual isoform led to a substantial
inhibition of CEP4 phosphorylation relative to the scrambled control (SC) shRNA plasmid.
When compared with that of SC-treated cells, inhibition of CEP4 phosphorylation averaged
60% with either the PKC- or PKC- shRNA reagent, and >85% with PKC- shRNA (-2),
where each value represents the average of three independent experiments (Figure 3.6B).
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These findings suggest that each of the three PKC isoforms phosphorylates CEP4 in the
intracellular environment.

Figure 3.6: Knockdown of individual PKC isoforms blocks CEP4 phosphorylation. MCF-10A
cells were cultured in six-well plates and transiently transfected with a 3:1 mixture of PolyExpress
reagent (6l) and a plasmid (2g) encoding shRNA that targeted a single PKC isoform (, , or ).
Following incubation of the cells at 37 °C for 96 hours, lysates were prepared and normalized for total
protein. An aliquot of each lysate (30 μg) was applied for demonstration of knockdown of each
isoform using Western blotting by use of an isoform-specific antibody, as shown in A. The remaining
portion of each lysate (100 μg) was immunoprecipitated with anti-CEP4 (3 μg), and the resulting
immunopellets were analyzed in duplicate Western blots for either phosphorylated CEP4 (PKC
substrate antibody, 1:1500 dilution) or for total CEP4 protein (anti-CEP4, 1:2000 dilution), as shown
in B. In order to demonstrate the specificity of shRNA reagent for PKC-, the expression of PKC- and  was analyzed with Western blot staining with PKC PKC- -and 
(1:1000) using equal amount of lysates (30 μg), as shown in C. Western blots are representative of
three independent experiments.

3.2.5 Interference of Intracellular CEP4 Phosphorylation by Kinase-Defective
Mutants of PKC Isoforms
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In a complementary approach, MCF-10A cells were transfected with individual kinase-dead
(KD) hemagglutinin (HA)-tagged mutants for isoform - (K368R), - (K376R), or -
(K281M), and their interference in CEP4 phosphorylation was evaluated under conditions of
DAG-lactone stimulation. In each lysate, the expression of a kinase-dead mutant was verified
by Western blot with an HA-tag antibody (Figure 3.7). Lysates were immunoprecipitated
with anti-CEP4, and the resulting immunopellets were analyzed for phosphorylated CEP4
and for total CEP4 protein by Western blotting. The results, shown in Figure 3.7, reveal a
substantial dominant negative effect on CEP4 phosphorylation by the KD mutants of PKC -
and - averaging 40−70% for three independent experiments. However, no significant
interference (<10%) was observed with KD-PKC- that may have had limited access to
CEP4. The agreement of the shRNA and kinase-dead mutant experiments for PKC- and -
is further evidence that CEP4 is a substrate for both isoforms.

Figure 3.7: Kinase-dead mutants for PKC-α and -δ interfere with phosphorylation of CEP4.
MCF-10A cells were cultured on 60-mm plates and transfected with a 3:1 mixture of PolyExpress
reagent (15l) and plasmid (5g) encoding the HA-tagged, kinase-dead (KD) mutant for each PKC
isoform (KD, KD, or KD) or the vector control (VC). Expression of HA-tagged KD mutants was
verified in each whole cell lysate (50 μg/lane) by probing with the anti-HA tag (1:1000). CEP4 was
immunoprecipitated from each cell lysate with anti-CEP4, and the pellets were evaluated for
phosphorylated CEP4 (P-CEP4) by Western blotting with the PKC substrate antibody (1:1500). An
equivalent CEP4 content for all samples was established by probing immunopellets in a duplicate blot
with anti-CEP4 (1:2000). The results are representative of three independent experiments.
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3.3: Discussion
In a recent application of the traceable kinase method, we defined substrate profiles of the
PKC isoforms in MCF-10A cells. Some proteins that co-immunoprecipitated with traceable
PKC-- and - had been already identified as PKC substrates (e.g. VASP, IQGAP-1,
MAP4, and -tubulin) which validates the effectiveness of the traceable kinase method with
these cells (Table 3.1). Likewise, some proteins that co-immunoprecipitated with traceable
kinase mutants were potential substrates in MCF-10A cells because they contained one or
more PKC consensus sites (Table 3.1). Several proteins that are GTPase-related and have a
known effect on cancer-related phenotypes, namely ROCK1, CEP4, PAK2 and CLASP1,
were tested to determine whether they serve as PKC substrates both in vitro and in MCF-10A
cells.
As shown by in vitro kinase assay, pure recombinant PKC-, - or - each phosphorylated
pure, recombinant CEP4 (Figure 3.3). In MCF-10A cells, CEP4 also underwent
phosphorylation in response to DAG-lactone (Figure 3.4A). It was concluded that only CEP4
was a PKC substrate in MCF-10A cells. With regard to the other three candidates, ROCK1
was not a PKC substrate since it did not undergo phosphorylation in vitro and in MCF-10A
cells (X. Chen, Ph.D. Thesis, 2010) (Figure 3.2). Recombinant PKC isoforms - and -
proteins phosphorylated PAK2 but not CLASP1 recombinant protein (Figure 3.3). However,
in MCF-10A cells, neither PAK2 nor CLASP1 showed any increased phosphorylation
following stimulation by DAG-lactone (Figure 3.4B, 3.4C). Thus, ROCK1, PAK2, and
CLASP1 are not PKC substrates in MCF-10A cells. Their co-immunoprecipitation with
traceable PKC mutants suggests that they are nonetheless physically associated with PKC in
the intracellular environment.
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It is notable that there are five structurally related human CEP isoforms, of which CEP4 is the
only member to possess a canonical PKC consensus site at Ser-18 (two pairs of cationic
residues flanking a serine or threonine residue). CEP4 was phosphorylated in a stoichiometric
ratio of almost 4:1 (moles of phospho-CEP4 per mole of CEP4) in DAG-lactone stimulated
MCF-10A cells (Figure 3.5). Therefore, it is likely that there are additional sites being
modified by DAG-stimulated PKC isoforms. Inspection of the human CEP4 primary
sequence shows that in addition to a full consensus site at Ser-18, there are three partial
consensus sites (two cationic residues on one side of a serine residue) located at Ser-77, Ser80, and Ser-86. The significance of these proposed sites of phosphorylation to CEP4 function
provides an avenue for further investigation that will be explored in Chapter 4.
In MCF-10A cells, phosphorylation of CEP4 in response to DAG-lactone was shown to be
impaired by individual isoform-specific shRNA reagents or kinase-dead mutants of either
PKC- or PKC-Figure 3.6, 3.7. DAG-lactone, a cell-permeable PKC activator, selectively
activates cPKC (PKC-) and nPKC (PKC-), but does not stimulate aPKC (PKC-) (GarciaBermejo et al., 2002). The loss of DAG-stimulated CEP4 phosphorylation by PKC-
knockdown was surprising because it implied that this isoform, which is insensitive to DAG,
phosphorylates CEP4 only in DAG-treated control cells. The possibility that, in addition to
PKC-, the two PKC- shRNA reagents also silenced DAG-sensitive PKC isoforms was
considered. However, no effect on either PKC- or PKC- expression accompanied PKC-
knockdown (Figure 3.6C). A plausible explanation is that DAG is known to cause
recruitment of PKC-ζ to the plasma membrane via DAG-stimulated PKC isoforms that
consequently activate the MAP kinase cascade, as recently reported for bronchial epithelial
cells stimulated with phorbol esters. It is further noted that blockade of DAG-stimulated
CEP4 phosphorylation by silencing of native PKC-ζ (Figure 3.6C) is inconsistent with the
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lack of interference by the kinase-dead PKC-ζ mutant (Figure 3.7). A reasonable explanation
is that, unlike the native enzyme, the kinase-dead mutant had limited access to CEP4. For
example, kinase-dead PKC-ζ may not have been able to bind CEP4 because its substrate
binding site was already occupied by a high-affinity substrate whose release depended upon
being phosphorylated. Nevertheless, the outcome produced by silencing native PKC-by
each of two different shRNA reagents clearly demonstrated the role of this isoform in CEP4
phosphorylation. The efforts taken here to establish which of the three PKC isoforms
phosphorylate CEP4 in the intracellular environment has led us to conclude that CEP4 serves
as a substrate for all three PKC isoforms.
A number of studies over the past few years have revealed that the Rho GTPases and their
effector proteins play important roles in human breast cancer, especially in invasion and
metastasis. An earlier study conducted by the Rotenberg laboratory (Sun and Rotenberg,
1999) demonstrated that Rho GTPases were functionally involved in phenotypes produced by
PKC- overexpression in MCF-10A cells. In that initial study, a dominant negative mutant
of Rac1 inhibited PKC--induced motility by 40%. In another example, the knockdown of
PKC- in MDA-MB-231 cells, an aggressive breast cancer cell line with elevated PKC-
levels, was shown to significantly decrease tumor metastasis. Moreover, PKC-deficient
clones were found to have lower Rho GTPase protein levels and activation (Pan et al., 2005).
In this chapter, CEP4, a Cdc42 effector protein, was shown to be a PKC substrate in MCF10A cells. One avenue for further investigation will be to determine if PKC-mediated
phosphorylation of CEP4 alters its binding affinity for activated Cdc42, thereby modulating
CEP4 and Cdc42 signaling pathways and producing one or more phenotypes previously
attributed to PKC in human breast cells. This objective will be pursued in the next chapter
(Chapter 4).
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Chapter 4: Characterization of The Functional
Significance of CEP4 in MCF-10A Cells
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4.1: Introduction
RhoA protein was first identified by Richard Axel’s group in 1985 due to its homology to
Ras in Aplysia (Madaule and Axel, 1985). Since that time, at least 20 additional Rho-related
family members have been identified in mammals. Rho, Rac and Cdc42 are the most
extensively studied members due to their significance in regulating the organization of actin
filaments during morphogenesis and migration of mammalian cells (Hall, 1994; Nobes and
Hall, 1995, 1999; Schmitz et al., 2000). Rho GTPases act as molecular switches, cycling
between an active GTP-bound state and an inactive GDP-bound state in order to direct
signaling pathways that produce cellular responses such as motility.

Figure 4.1: Rho Family GTPases in Breast cancer. Rho Family GTPases are involved in different
stages of cancer progession: dedifferentiation and upregulation of uncontrolled proliferation,
angiogenesis, invasion and metastasis (Zhang and Nie, 2011).
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Rho GTPase signaling pathways are thought to contribute to human breast cancer initiation
and progression by regulating growth, angiogenesis, invasion and metastasis of breast cancer
cells (Figure 4.1). Altered expression of a Rho GTPase, changes in its activation status, or
changes in the expression level of its effector proteins, all were found to occur in human
breast cancer. RhoA was found overexpressed in breast tumor tissues but not in the normal
tissues (Fritz et al., 2002). Microarray analysis showed that over-expression of RhoC genes in
MCF-10A breast cells was associated with invasion and metastasis (Wu et al., 2004).
Immunohistochemical staining of Rac1 showed weak expression in benign breast disease but
high expression levels in primary breast tumors (Schnelzer et al., 2000). Furthermore, the
Rac/p21 activated kinase (PAK) signaling pathway is essential for receptor tyrosine kinase
ErbB2-mediated transformation of human breast epithelial cancer cells (Muthuswamy and
Chernoff, 2011). In addition, PAK2, an effector protein of both Rac1 and Cdc42, was
implicated in breast carcinoma cells invasion and migration by regulating formation of focal
adhesion and lamellipodia (Coniglio et al., 2008). Cdc42 is also known to be involved in
human breast carcinogenesis. For example, the expression of a dominant negative mutant of
Cdc42 reduced the number of focal contacts, inhibited colony formation in soft agar and
affected cell growth in vivo (Fritz et al., 1999). The activation of the downstream effectorsPAK2 and N-WASP by Cdc42 is also important for amoeboid movements (Gadea et al.,
2008). In addition, Cdc42-mediated activation of MRCK was required for collective
migration of carcinoma cells (Gaggioli et al., 2007). However, several recent studies
suggested Cdc42 may function as a tumor suppressor. The Zuo group showed that Cdc42
negatively regulated intrinsic migration/invasion of highly aggressive breast cancer cells
(MDA-MB-231 and C3L5 cell line) (Zuo et al., 2012). Although Rho GTPases have been
implicated in cellular transformation in breast cancer, their role in cancer development is
complicated and may be cell type-specific.
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In 1999, the Rotenberg group showed that in MCF-10A cells engineered to over-express
PKC-, the dominant negative forms of Rac1, Rho or Cdc42 can each eliminate the
formation of stress fibers. However, only the dominant negative form of Rac1 suppressed the
motility phenotype induced by over-expressed PKC-. This finding indicated that Rac1
participates in PKC-directed signaling pathways. In 2004, Gutierrez’s group demonstrated
that the phosphorylation of IQGAP (an effector of Cdc42 and Rac1) by PKC-enhanced its
binding with Cdc42-ND (nucleotide-depleted) and made the phosphorylated IQGAP1 behave
as a Cdc42 inhibitor (Grohmanova et al., 2004). In 2014, the Rotenberg group reported that
the phosphorylation of -tubulin by PKC induces the activation of Rac1 and also stimulates
Rac1-dependent cell motility (De et al., 2014). Thus, PKC-mediated phosphorylation can
modulate the motility signaling pathway by involving the small GTPases.
A recent study from the Rotenberg lab demonstrated that CEP4 is also a PKC substrate in
MCF-10 cells (Chen et al., 2012). CEP4 was first reported to be a novel Cdc42 effector
protein together with other members of the CEP family in 2001 (Hirsch et al., 2001). CEPs
were showed to bind strongly to immobilized GST-Cdc42 but not to Rac1. CEPs interacted
with Cdc42 through their CRIB (Cdc42/Rac interactive binding) domain and functioned as
downstream effector proteins in regulating actin reorganization and alteration of cell
morphology.
In the present work, MCF-10A cells was chosen as a model since this cell line expresses low
levels of PKC isoforms so that the function of CEP4 and its phosphorylation site mutants can
be studied against a low background. In this Chapter, the significance of CEP4
phosphorylation to PKC-related phenotypes is explored.

4.2: Results
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4.2.1 Preparation and Characterization of Single Site Mutants of CEP4 in MCF-10A
Cells
Among the five members of the CEP family, CEP4 is the only member that contains PKC
consensus sites. In a determination of the number of sites phosphorylated by PKC, the ratio
of phospho-CEP4 to total CEP4 in DAG-lactone treated cells was between 3:1 and 4:1 (Chen
et al., 2012). That initial calculation suggested the possibility that there is more than one site
that undergoes phosphorylation by DAG-stimulated PKC isoforms.
Potential PKC sites were identified by the presence of a consensus sequence, which consists
of a Ser or Thr flanked by one or two basic residues. Four sites were identified at Ser-18, Ser77, Ser-80, and Ser-86 (Figure 4.2A). In order to investigate the functional significance of
these candidate phosphorylation sites in CEP4, a pseudo-phosphorylated (Ser  Asp) mutant
of each site was constructed by site-directed mutagenesis. Upon identification of the
phenotypically significant site(s), a phosphorylation-resistant mutant (Ser  Ala) was also
developed in order to determine whether it has a negative impact on a PKC-associated
phenotype (motility, proliferation or morphology).
A pCMV6 plasmid encoding the wildtype CEP4 was obtained from a commercial source and
used for these studies. The plasmid conferred FLAG and Myc tags to the CEP4 protein upon
expression. Plasmids encoding CEP4-S18D, CEP4-S77D, CEP4-S80D or CEP4-S86D were
prepared and verified by a commercial sequencing facility. Following transfection of each
construct into MCF-10A cells, the expression level of each mutant (~48kDa) was
demonstrated by Western blot analysis with a Myc antibody (Figure 4.2B). To determine the
functional significance of each mutated site, a migration assay was performed with each
pseudo-phosphorylated mutant individually expressed in MCF-10A cells. MCF-10A cells
were transfected with CEP4-S18D, CEP4-S77D, CEP4-S80D, CEP4-S86D, or the vector
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control. By use of a 10-well glass slide pre-coated with 1% BSA, the cells were seeded into
the well through a cell sedimentation manifold (8000 cells/well) to establish a tight circular
monolayer. Following overnight incubation and subsequent removal of the manifold, each
circle was imaged at t = 0h and t = 6h with Motic Image software. The numerical difference
in the areas at t=0h and t=6h were plotted graphically, as shown in Figure 4.2C. The CEP4S80D transfectants exhibited the strongest motile behavior that had a 2-fold higher motility as
compared with the CEP4 -WT. Cells expressing the CEP4-18D mutant displayed the second
strongest motility that was 1.3-fold higher as compared to the WT-CEP4, whereas the CEP488D mutant exhibited a level of motility that was equivalent to the WT and the CEP4-77D
mutant showed no enhancement whatsoever. These results demonstrated that CEP4-S18D
and CEP4-S80D had the strongest effects on motile behavior and implied that Ser-18 and
Ser-80 are the sites of PKC phosphorylation having functional significance.

4.2.2 Preparation and Testing of Phosphorylation-resistant Mutants of CEP4
To study the functional significance of phosphorylation at Ser-18 and Ser-80,
phosphorylation-resistant mutants were created as single site mutants (S18A, S80A) and as a
double mutant (S18A-80A). The expression level of the three mutant proteins in MCF-10A
transfectants was confirmed by Western blot (Figure 4.3A). Next MCF-10A transfectants
were assessed for a change in their motility by the cell sedimentation method. At t = 0 h, the
medium were replaced with fresh medium containing 10 M DAG-lactone or 0.05% DMSO
(v/v) as a control. DAG-lactone stimulates endogenous PKC activity that in turn enhances
motility of MCF-10A cells. Motility values were calculated by the difference in the areas
occupied by the cells at t=0h and t=6h, and the results were plotted in Figure 4.3B. The
S18A-80A double mutant was the most effective in inhibiting DAG-lactone stimulated
motility by 50%.
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Figure 4.2: Preparation and characterization of CEP4 pseudo-phosphorylated single site
mutants. (A) Amino terminal sequence of human CEP4 where the PKC consensus sites (full or
partial) are underlined and the serine residues that could serve as potential phosphorylation sites (red)
are identified by their position. (B) Myc-tagged CEP4 mutants were prepared in which an individual
serine (S) was replaced with aspartate (D) residue, followed by its expression in MCF-10A human
breast cells. To demonstrate expression of the mutant proteins relative to a vector control (VC),
Western blot analysis of whole cell lysates (50g/lane) was performed with anti-Myc (1:1000). Anti-actin (1: 5000) was used to judge equivalent sample loading. (C) For assay of cell motility, each
mutant CEP4-encoding plasmid was transfected into MCF-10A cells. After 48 h, the transfected cells
were plated on 10-well glass slide and incubated overnight at 37oC. Cell motility was measured in
triplicate by the cell sedimentation assay (described in the ‘Methods’). Images were acquired by a 4X
objective at t = 0 h and t = 6 h. The difference in the area between the two time points was averaged.
The values are reported as the average of triplicate measurements + s.d. and are representative of three
independent experiments. Statistical analysis was performed with the Student’s t-test that compared
the VC condition with each selected mutant (**P < 0.00001).

The next step was to assess the impact of Ser-18 and Ser-80 on the extent of CEP4
phosphorylation in MCF-10A cells under PKC-activated conditions. MCF-10A cells were
transfected with VC, CEP4-WT, CEP4-S18A, CEP4-S80A or CEP4-S18A/80A. Following
transfection, the cells were treated with DAG-lactone (10 M) or DMSO for 1h at 37oC. The
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cells were lysed in hypotonic detergent-free IP buffer in order to avoid the interference of
detergent during the immunoprecipitation and the samples were normalized for total protein
content. CEP4 protein was immunoprecipitated from each sample with EZ view anti-FLAG
beads, and the immunopellets were analyzed by Western blot.

Figure 4.3: Expression of phosphorylation-resistant CEP4 mutants block DAG-lactone-induced
cell motility. A. Plasmids encoding CEP4-WT, CEP4-18A, CEP4-80A and CEP4-18A/80A were
transfected into MCF-10A cells. A representative Western blot of whole cell lysates (50 g per lane)
showed a similar level of CEP4 expression with Myc antibody (1:1000). A -actin antibody (1:5000)
was used to establish equivalent sample loading. B. CEP4 WT and mutants were tested for their
impact on motility of MCF-10A cells treated with 10M DAG-lactone. The results are representative
of three independent experiments. The values are reported as the average of triplicate measurements +
s.d. and are representative of three independent experiments. Statistical analysis was performed with
the Student’s t-test that compared each mutant with the VC condition (*P < 0.01, **P < 0.0001).
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Figure 4.4: Expression of phosphorylation-resistant CEP4 mutants inhibit DAG-lactonestimulated phosphorylation of CEP4. A. Wildtype (WT)-CEP4 or single site and double site
mutants corresponding to S18A, S80A, or S18A/S80A-CEP4 were transfected into MCF-10A cells.
After 48h incubation at 37oC, the cells were treated with DAG-lactone (10M) or DMSO (0.05%
v/v) for 1h at 37oC, followed by preparation of a whole cell lysate (150 g/sample) with detergentfree lysis buffer [20 mM TRIS (pH 7.4), 2mM MgCl2, 2 mM EGTA and 1 mM DTT, 10 μM bisindoleylmaleimide, 0.1% protease inhibitors, and 1% phosphatase inhibitors]. The lysate was precleared using 30 μl mouse IgG-agarose beads, followed by immunoprecipitation with 60 μl antiFLAG agarose beads (described in ‘Methods’). The pellets were analyzed by Western blot with PKC
substrate antibody (1:1500) that recognizes the phosphorylated PKC substrate consensus sites in
phospho-CEP4, or CEP4 antibody (1:2000) as loading control. B. Quantitation of the signal intensity
was carried out with Image J software.

Phospho-CEP4 was detected with the PKC substrate antibody (detects the phosphorylated
PKC consensus site) and the expression of total CEP4 was detected with human CEP4
antibody. In Figure 4.4A, the results showed that CEP4-WT was strongly phosphorylated
when the cells were stimulated by DAG-lactone. Compared to DAG-lactone stimulated
phosphorylation of CEP4-WT, the single site phosphorylation-resistant mutants – (S18A or
S80A) each suppressed the DAG-lactone-induced phosphorylation of CEP4 by 75-80%.
However, expression of the CEP4S18A/80A mutant eliminated the DAG-lactone-induced
phosphorylation signal to below that of the basal condition (VC). These results were
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quantified by Image J shown in Figure 4.4B. Taken together, Ser-18 and Ser-80 appear to be
the major phosphorylation sites having functional significance. Therefore, CEP4 18D/80D,
(the pseudo-phosphorylated double mutant), and CEP4 18A/80A (the phosphorylationresistant double mutant), were used in subsequent experiments to investigate their phenotypic
effects in MCF-10A cells.

4.2.3 Evaluation of CEP4 Mutants in Additional Phenotypes
Previous studies reported that over-expression of PKC- in non-transformed MCF-10A
human breast cells causes a pronounced increase in motility with loss of detectable of Ecadherin, decreased proliferation (due to slow passage through G1 of the cell cycle) and
radical alterations in morphology (extensive and well-defined organization of actin stress
fibers) (Sun and Rotenberg 1999). In view of the importance of PKC activity to cancerrelated phenotypes, pseudo-phosphorylated CEP4 was explored as the agent that produces
these phenotypes.
4.2.3.I Proliferation Assay of CEP4 Mutants in MCF-10A Cells
Overexpression of PKC- in MCF-10A cells was previously shown to inhibit cell
proliferation by slowing the passage of cells through the G1 stage of the cell cycle (Sun and
Rotenberg, 1999). To determine if phospho-CEP4 similarly inhibits cell proliferation, an
assay with Alamar Blue was performed on MCF-10A cells that expressed a double mutant,
CEP4-18A/80A or CEP4-18D/80D. In addition to staining cells, the Alamar Blue reagent acts
as a fluorimetric indicator of metabolic activity. MCF-10A cells were transfected with a
CEP4 double mutant or the vector control. After 48h at 37oC, the transfectants were re-plated
into 96-well plates, and the Alamar Blue reagent was added to each well to a final
concentration of 4% (v/v).
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Figure 4.5: The impact of phosphorylation-resistant/pseudo-phosphorylated CEP4 mutants on
proliferation in MCF-10A cells. Plasmids encoding CEP4-18A/80A and CEP4-18D/80D were
transiently transfected into MCF-10A cells. Forty-eight hours post-transfection, the cells were replated into 96-well plates. The proliferation assay of the transfectants was assessed using the Alamar
Blue reagent, as described in the “Methods” section. The fluorescence intensity was measured each
day for 4 days.

The plates were incubated at 37oC, 5% CO2 and daily measurements were made for 4 days.
Since the fluorescence intensity is sensitive to temperature, the plates were allowed to
equilibrate to room temperature for 30 min prior to fluorescence measurement using a 96well plate reader at ex = 530 nm and em = 590 nmThe plates were returned to the incubator
until the next time point. Cell proliferation rates displayed no significant difference in MCF10A cells expressing a mutant CEP4 or VC (Figure 4.5). The lack of effect may be due to
CEP4 mutants having been transiently transfected into MCF-10A cells whereby the
expression was highest at 48h. Thus, when cells were subsequently plated into a 96-well plate
post-transfection and monitored for 4 days to measure the proliferation, the transfected cells
may have lost the plasmid as the assay progressed. Therefore, this proliferation assay may not
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be an accurate representation of the impact on proliferation by the mutants. The best way to
characterize a proliferation effect is to work with stably transfected cell lines, as will be
discussed in Chapter 5.

4.2.3.II Immunocytochemistry of MCF-10A Cells Expressing Double Mutants of CEP4
The actin cytoskeleton has a fundamental role in various cellular processes such as migration,
morphogenesis, cytokinesis, endocytosis and phagocytosis. Small Rho GTPases have been
studied as components that regulate and organize actin structure (Hall, 1994; Nobes and Hall,
1995; Ridley and Hall, 1992). In NIH-3T3 fibroblasts cells, CEPs were shown to induce
pseudopodia formation through the Cdc42 pathway and was visualized by F-actin staining
(Hirsch et al., 2001). In primary keratinocytes, CEP2 and CEP5-expressing cells showed less
F-actin staining at the adherent belt and displayed thin stress fibers that extended throughout
the cell body, similar to the effect caused by the constitutively active form Cdc42-Q61L
(Hirsch et al., 2001). On the basis of these results, CEPs were proposed to act as downstream
effectors of Cdc42 that reorganize the actin cytoskeleton and produce cell morphology
changes. However, in Madin-Darby canine kidney cells (MDCK), Cdc42 affected the cortical
actin structure and distribution of the actin cytoskeleton at cell tight junctions but there were
undetectable CEP-induced changes in actin organization, suggesting that CEP and Cdc42
acted independently (Rojas et al., 2001). Therefore, we examined whether the distribution of
F-actin and the morphology of cells were altered by the expression of the phosphorylation
site mutants of CEP4 in MCF-10A cells.
Vector control (VC) cells or those expressing CEP4 WT, CEP4-18D/80D or CEP4-18A/80A
were cultured for 24h under serum-free conditions on coverslips in 6-well plates. The cells
were stained with Myc antibody to recognize the cells transfected with a CEP4 plasmid
(shown in green). The distribution of F-actin and the cell morphology were determined by
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incubating fixed and permeabilized cells with rhodamine-phalloidin (shown in red) and
examining stained cells with a Zeiss fluorescence microscope (Figure 4.6A). After
transfection, CEP4 expression was identified in the cytoplasm and at the cell membrane,
regardless of whether CEP4 was expressed as the wildtype or mutant protein. In CEP418D/80D expressing cells, actin filaments were well-defined throughout the entire cell body
(Figure 4.6A). In approximately 85% of cells expressing CEP4-18D/80D, we observed
filopodia which are long, thin actin filaments that project from the cell surface.
Approximately 50% of CEP4-WT-expressing cells also showed these structures. In contrast,
only 10% of cells expressing CEP4-18A/80A displayed filopodia, similar to the vector
control cells (Figure 4.6B). In summary, these observations indicated that the actin structure
in MCF-10A cells is responsive to the expression of pseudo-phosphorylated CEP4.
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Figure 4.6: Pseudo-phosphorylated CEP4 mutants induce filopodia formation in MCF-10A
cells. A. MCF-10A cells were transfected with Myc-tagged wildtype (WT)-CEP4, CEP4-18D/80D or
S18A/S80A. Twenty-four hours post-transfection, the medium was replaced with serum-free media
and the cells were incubated overnight. On the second day, the serum-starved cells were fixed by 4%
paraformaldehyde. CEP4 expression was detected by rabbit monoclonal antibodies against Myc
epitope tag (1:300) followed by staining with FITC-conjugated goat anti-rabbit IgG (1:300). F-actin
was visualized by staining with rhodamine-phalloidin (100 nM). Images were acquired at 63x
objective. Bar, 10m. B. Cells expressing filopodia are represented as a fraction of the total number of
transfected cells, where a total of 50 cells were analyzed per condition over three independent
experiments. The values are reported as the average of triplicate measurements + s.d. Statistical
analysis was performed with the Student’s t-test that compared values obtained for cells expressing
A/A and D/D mutants (**P < 0.0001).

IQ-domain GTPase-activating proteins (IQGAPs) comprise a family of multi-domain
proteins that act as a scaffold for numerous interacting partners while transducing
extracellular signals that influence mitogenic, morphological and migratory cell behavior.
IQGAP1 is the most studied member of the family due to its role in actin reorganization that
affects cell-cell adhesion, cell polarization and cell migration (Johnson et al., 2009). There is
mounting evidence showing that IQGAP1 contributes to cancer progression by regulating the
signaling pathway in cell proliferation and stimulation of cell motility and invasion (Johnson
et al., 2009; White et al., 2009). IQGAP1 was initially identified as a Cdc42/Rac1 effector
protein and was also demonstrated to participate in Cdc42/Rac1- induced cell migration and
invasion (Fukata, 1996; Mataraza et al., 2003). IQGAP forms a ternary complex with
activated Cdc42 or Rac1 and the adenomatous polyposis coli (APC) protein leading to
regulate actin structure (Watanabe et al., 2004). Since we observed filopodia formation and
enhanced cell motility with the expression of phospho-CEP4, we were interested in
determining whether phosphorylation of CEP4 modulates actin structure and cell migration
by affecting localization of IQGAP1. To address this question, we transfected MCF-10A cells
with CEP4-18A/80A or CEP4-18D/80D (shown in red) and stained with IQGAP1 antibody
(shown in green). As shown in Figure 4.7A and 4.7B, CEP4-18D/80D expression was
correlated with the association of IQGAP1 with cell-cell contacts for non-migrating cells and
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at the leading edge and filopodia of moving cells. In contrast, CEP4-18A/80A expression
was correlated with primarily a cytoplasmic location of IQGAP1, with a much lower level of
IQGAP evident at cell-cell junctions and at the cell surface (Figure 4.7A and 4.7B). It is
noted that expression of neither CEP4 mutant affected the total level of IQGAP1 expression
(Figure 4.7C). However, the results suggested that the phosphorylation of CEP4 might
interfere in the sub-cellular distribution of IQGAP. In this regard, phosphorylation of CEP4
may activate the Cdc42/Rac1 pathway.
E-cadherin is a calcium-dependent cell-cell adhesion molecule with important roles in cell
adhesion and migration. PKC- overexpression in MCF-10A cells resulted in the loss of
detectable E-cadherin (Sun and Rotenberg, 1999), and expression of Cdc42-Q61L and CEPs
also resulted in reduced levels of E-cadherin at adherens junctions (Hirsch et al., 2001).
Therefore, we performed immunocytochemistry to study the distribution of E-cadherin at
adherens junctions in cells expressing a CEP4 double mutant. As shown in Figure 4.8, no
detectable difference was found in the distribution or expression of E-cadherin (shown in red)
between the two mutants (shown in green) in MCF-10A cells.
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Figure 4.7: IQGAP immunofluorescence at the cell leading edge and cell-cell junctions of
CEP4 mutants expressing MCF-10A cells. Myc-tagged CEP4-S18D/80D or CEP4-S18A/S80A
were transfected into MCF-10A cells and fixed with paraformaldehyde 48h after transfection. CEP4
expression (shown in red) was detected by a mouse monoclonal antibody against the Myc epitope
tag (1:300) followed by staining with Alexa Fluor 594-conjugated goat anti-mouse secondary
antibody (1:300). IQGAP was visualized by staining with rabbit monoclonal anti-IQGAP
(shown in green) at a 1:200 dilution followed by staining with FITC-conjugated goat anti-rabbit
IgG (1:300). A. Images show the location of IQGAP near cell-cell junctions only in cells expressing
CEP4-18D/80D. B. Images show IQGAP signals near the cell leading edge and associated filopodia
only in cells expressing CEP4-18D/80D. Images were acquired with a 63x objective. Scale bar is 10
μm. C. MCF-10A cells were transfected with Myc-tagged CEP4-WT, CEP4-S18D/80D or CEP4S18A/S80A. The WT transfectants were treated with or without DAG-lactone (10 M). Whole cell
lysates were prepared and analyzed by Western blot (75 g/lane). The expression level of IQGAP
was detected by anti-IQGAP (1:1000).
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B.
Figure 4.8: E-cadherin immunofluorescence at cell-cell contacts of CEP4 mutants in MCF-10A
cells. Myc-tagged CEP4-WT, CEP4-S18D/80D or CEP4-S18A/S80A were transfected into MCF-10A
cells and fixed 48h post- transfection. CEP4-18D/80D and CEP4-18A/80A were detected with rabbit
anti-Myc antibody (1:300) followed by staining with FITC-conjugated goat-anti rabbit antibody
(1:300). E-cadherin was detected with mouse monoclonal anti-E-cadherin diluted to 1:150

followed by staining with Fluor 594-conjugated goat anti-mouse secondary antibodies (red,
1:300). Images were acquired with a 63x objective. Scale bar is 10 μm. C. MCF-10A cells were
transfected with Myc-tagged CEP4-WT, CEP4-S18D/80D or CEP4-S18A/S80A. The wildtype
transfectants were treated with or without DAG-lactone (10 M). Whole cell lysates were prepared
and analyzed by Western blot (75 g/lane). The expression level of E-cadherin was detected by antiE-cadherin (1:1000).
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4.2.4 Phosphorylation of CEP4 Alters Its Binding Affinity for Cdc42
A previous report demonstrated CEPs bind to Cdc42 in a GTP-dependent fashion, but not to
Rac1 or Rho (Hirsch et al., 2001). Other studies have suggested that PKC-mediated
phosphorylation influences the binding activity of accessory proteins (like GDI or effector
proteins) that regulated the activation state of Rho GTPase (Grohmanova et al., 2004; Mehta
et al., 2001). The next step was to test the hypothesis that phosphorylation of CEP4 alters its
affinity for Cdc42. We used glutathione-agarose beads to bind constitutively active
glutathione-S-transferase (GST)-tagged-Cdc42Q61L that had been prepared from bacterial
cells. MCF-10A cells expressing the Myc-tagged CEP4-WT (treated with or without DAGlactone) or expressing CEP4 18A/80A or CEP4-18D/80D were prepared into whole cell
lysates. Each lysate was incubated with the immobilized GST-Cdc42Q61L; the beads were
washed, and the material remaining on the beads was analyzed by Western blot with antiMyc. It was observed that DAG-lactone treatment-induced phosphorylation of CEP4-WT or
the pseudo-phosphorylated mutant each exhibited a very weak interaction with immobilized
GST-Cdc42Q61L. Whereas WT-CEP4 isolated from untreated cells or the phosphorylationresistant CEP4 mutant each displayed strong binding affinity for Cdc42-Q61L. The results
suggested that phosphorylation of CEP4 greatly diminishes its affinity for Cdc42, presumably
causing the release of Cdc42 to other downstream effectors. Since the pseudo-phosphorylated
mutant of CEP4 also produced enhanced cell motility and induced filopodia, it is possible
that phosphorylated CEP4 interacts with other pathways to stimulate cell motility after its
release from Cdc42.
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Figure 4.9: Binding of CEP4 double mutants to constitutively active GST-Cdc42-Q61L. MCF10A cells were transfected with Myc-tagged WT plasmid or a mutant-encoding CEP4 plasmid.
Where indicated, the WT-CEP4-expressing cells were treated with 10 M DAG-lactone or DMSO
(0.05%, v/v). Following bacterial expression and immobilization of GST-Cdc42-Q61L on glutathione
beads, a MCF-10A cell lysate containing WT or mutant CEP4 was incubated with the beads for 40
min. After centrifugation for 5 minutes at 10,000 x g and washing with detergent-free lysis buffer
three times, the pellets were analyzed by Western blot with anti-Myc (1:1000) to determine the
amount of bound CEP4 protein in each condition. The blot was also analyzed with anti-Cdc42
(1:5000) to establish an equivalent loaded amount of pelleted Cdc42-Q61L.

4.2.5 Phosphorylated CEP4 Activates Rac1
PKC-mediated phosphorylation of CEP4 produces elevated cell motility which had been
previously attributed to PKC in MCF-10A human breast cells. An earlier study from our
laboratory demonstrated that Rac1 was functionally involved in the motility phenotype
produced by PKC- expression in these cells (Sun and Rotenberg, 1999). Since we had
identified that phosphorylation of CEP4 causes its disassociation with Cdc42, it was of
interest to determine whether Rac1 was involved in phospho-CEP4-induced cell motility. For
this purpose, cell migration of cells expressing CEP4-18D/80D was measured under
conditions of Rac1 inhibition using the small molecule inhibitor NSC23766. This cellpermeable molecule prevents Rac1 activation to the GTP-bound form by inhibiting binding
of Rac1-specific guanine nucleotide exchange factors (GEFs), thereby keeping Rac1 in the
GDP-bound (inactive) state. In Figure 4.10B, it was observed that the Rac1 inhibitor
significantly inhibited migration induced by CEP4-18D/80D transfectants by 95%. Cdc42 has
been implicated in both stimulatory and inhibitory effect on cell motility. The phospho-CEP4
induced motility might also result in a Cdc42-stimulated pathway. Therefore, we also tested
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the impact of a Cdc42 inhibitor ML141 on cell migration of MCF-10A cells. ML141 is cell
permeable allosteric compound that acts as a potent, selective, reversible and non-competitive
inhibitor of Cdc42 GTPases. However, ML141 did not suppress the cell motility but rather
stimulated this phenotype regardless of which plasmid had been transfected into MCF-10A
cells (Figure 4.10A). These results suggested that Rac1 (but not Cdc42) participates in
phospho-CEP4-induced cell migration in MCF-10A cells.

Figure 4.10: The effect of a Rac1 inhibitor (NSC23766) and Cdc42 inhibitor (ML141) on
motility of MCF-10A cells transfected with CEP4 mutants. A. Triplicate samples of transfectants
expressing mutant CEP4 proteins or the vector control (VC) were treated with or without 5 M
ML141 (in DMSO) for 8 h during the entire period (8 h) that motility was being measured. The results
are representative of three independent experiments. The values are reported as the average of
triplicate measurements + s.d. Statistical analysis was performed with the Student’s t-test that
compared values obtained with and without Cdc42 inhibitor (*P < 0.0001). B. Triplicate samples of
transfectants expressing mutant CEP4 proteins or the vector control (VC) were treated with or without
50 M NSC23766 (in water) for 6 h during the entire period (6 h) that motility was being measured.
The results are representative of three independent experiments. The values are reported as the
average of triplicate measurements + s.d. Statistical analysis was performed with the Student’s t-test
that compared values obtained with and without Rac1 inhibitor (*P < 0.0001, **P < 0.000001).
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We next examined whether the Rac1 inhibitor also affected the phospho-CEP4-induced
alterations of morphology in MCF-10A cells. To address the role of Rac1 in the formation of
filopodia, we treated CEP4-18D/80D transfectants with 50 M Rac1 inhibitor for 2 hours,
followed by staining of the cells with rhodamine-phalloidin. Fluorescence microscopy (Zeiss)
indicated that compared with untreated cells expressing CEP418D/80D, of which 85%
displayed filopodia, only 10% of cells exhibited filopodia after treatment with the Rac1
inhibitor. It is noted that only 50% of cells exhibited filopodia after treatment with the Cdc42
inhibitor. These results indicated that phospho-CEP4 induces cell surface projections by a
mechanism that involves Rac1, and that Cdc42 contributes to a lesser extent to the formation
of these structures.

Figure 4.11: The effect of a Rac1 inhibitor (NSC23766) or Cdc42 inhibitor (ML141) on actin
structure of MCF-10A cells transfected with CEP4 mutants. MCF-10A cells expressing Myctagged pseudo-phosphorylated CEP4 mutant were treated with or without 50 M NSC23766 or 5 M
ML141 for 2 h, fixed with paraformaldehyde, and stained with rhodamine-phalloidin (100 nM) to
detect F-actin. Transfected cells were identified by GFP fluorescence with Myc-tagged rabbit mAb
(1:300) as described in the ‘Methods’section. Images were acquired with a 63x objective. Scale
bar is 10 μm.
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In order to investigate whether phospho-CEP4 activates small GTPases (especially Rac1), a
RhoA/Rac1/Cdc42 activation assay was performed. MCF-10A cells expressing CEP418D/80D or CEP4-18A-/80A were lysed and each lysate was incubated with either PAKPBD agarose (EMD-Millipore) to pull down any activated Rac1 and Cdc42, or Rhotekinagarose to pull down activated RhoA. Proteins present in pulled-down samples were resolved
by SDS-PAGE (12%) and probed with an antibody specific for Rac1, Cdc42, or RhoA. As
shown in Figure 4.12, cells expressing the CEP4-S18D-80D mutant exhibited stronger
signals for GTP-Rac1 than cells expressing the CEP4 18A-80A mutant or vector control. In
contrast, GTP-Cdc42 and GTP-RhoA signals were not affected by expression of either CEP4
mutant. Similar to previous findings with 6-tubulin mutants (De et al., 2014), there were
negligible activated Cdc42 signals in all conditions; whereas RhoA was strongly activated in
all conditions (data not shown). Thus, the expression of phospho-CEP4 stimulated the
activation of Rac1.

Figure 4.12: Western blot analysis of the level of activated Rac1, in response to CEP4 mutant
expression. CEP4-18A/80A (A/A) or CEP4-18D/80D (D/D) cDNA plasmids were transfected into
MCF-10A cells. Cell lysates were prepared as described in the ‘Methods’ and each cell lysate (600
g) was incubated with PAK-PBD beads (20 μg) for 2 h at 4oC with rotation. After washing the
pellets, the material was resolved by 12% SDS-PAGE and western transfer, and the blot was probed
with anti-Rac (Cell Signaling Technology; 1:500).

4.2.6 Identification of CEP4-Associated Proteins by the Tandem Affinity Purification
(TAP) Method

Since phospho-CEP4 could stimulate Rac1, phospho-CEP4 might directly interact with Rac1
or interact with some other protein that induces the activation of Rac1. In an effort to identify
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and characterize novel phospho-CEP4-interacting proteins, we carried out an analysis using
TAP (tandem affinity purification) methodology. The TAP method entails the purification of
a protein complex of interest under conditions that preserve protein-protein interactions. For
this procedure two affinity purification tags are employed - a streptavidin binding peptide
(SBP) and a calmodulin binding peptide (CBP), each of which is immobilized on a resin
(Figure 4.13). Any binding proteins eluted from the second column (CBP) are resolved by
SDS-PAGE and the gel is stained with Gelcode Blue. In our experiment, bands that were
evident with the CEP4-S18D/S80D mutant but absent with the CEP4-S18A/S80A mutant
were excised and analyzed by mass spectrometry (MS/MS).

Figure 4.13: Schematic diagram of purification of protein complexes by the Tandem Affinity
Purification method. To purify proteins by the TAP protocol, cell lysates were applied to the
streptavidin resin, and eluted with streptavidin elution buffer. The eluate is applied to a calmodulin
resin and eluted. The eluate from this second column is analyzed by SDS-PAGE (Agilent
Technologies).
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To prepare for this experiment, the full length of human Myc-tagged CEP418D/80D or
18A/80A (1000 bp) was cloned into the pCTAP vector (4500 bp) so that tandem affinity
purification (TAP) tags consisting of a streptavidin-binding peptide and a calmodulin-binding
peptide were fused in-frame to its COOH terminal of the CEP4 mutant. At least three clones
for each mutant were selected and expressed in MCF-10A cells to confirm the expression of
the TAP proteins. The pCTAP-CEP4-18D/80D or pCTAP-CEP4-18A/80A was transfected
into MCF-10A cells and the expression was confirmed by Western blot with anti-Myc
(Figure 4.14A). One clone from each of the two constructs was expressed in MCF-10A cells
followed by preparation of cell lysates (from three 10-cm plates at 80-90% confluence) by the
freeze/thaw method. Lysates were applied sequentially to the affinity columns, as described
in the Methods, and as shown schematically in Figure 4.13. The samples were resolved by
12% SDS-PAGE gel and stained with Gelcode Blue. When the patterns of protein bands were
compared between TAP-CEP4-18A/80A and TAP-CEP4-18D/80D samples, three major
bands at 250 kDa, 125 kDa and 44 kDa (indicated by red boxes) were unique to the TAPCEP4-18D/80D sample (Figure 4.14B).
To identify those proteins that specifically associated with CEP4-18D/80D, the observed 250
kDa, 125 kDa and 44 kDa bands were analyzed by MS/MS. The results are shown in Table
4.1. Potential associations between phospho-CEP4 and TEM4 or PARD6 were identified
since the two proteins are related to GTPase activity. To demonstrate direct interactions with
CEP4-S18D/S80D, co-immunoprecipitation (Co-IP) experiments were performed with
FLAG-tagged CEP4 mutant proteins using anti-FLAG-agarose. Western blot with specific
antibodies against the target protein was used to show the presence of the suspected binding
partner in the pellet. Interactions between phospho-CEP4 and PARD6, and phospho-CEP4
and TEM4 were detected since PARD6 and TEM4 signals were much stronger in CEP418D/80D complexes (Figure 4.15). In this experiment, we also observed that CEP4-18A/80A
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interacted strongly with endogenous Cdc42 whereas the CEP4-S18D/S80D bound weakly to
Cdc42 (Figure 4.15). This finding was in agreement with the in vitro GST-Cdc42-Q61L
binding assay that showed that phospho-CEP4 only weakly associated with Cdc42. These coimmunoprecipitation results suggested that phospho-CEP4 co-localizes and interacts with
TEM4 or PARD6 in intact cells.

Figure 4.14. Tandem affinity purification (TAP) of pseudo-phosphorylated CEP4 and its
binding proteins. Mutants of CEP4 were sub-cloned into a TAP vector that upon expression
conferred two affinity tags (peptide sequences corresponding to specific sites in streptavidin and
calmodulin) for affinity chromatography. The plasmids were transfected into MCF-10A cells and the
resulting cell lysates (3 mg/sample) were applied sequentially to two affinity binding columns. The
second eluate was resolved by 8% SDS-PAGE and detected by staining with Gelcode Blue. (A)
Western blot demonstrating expression of the TAP-CEP4 mutants as compared with the vector control
(VC) using anti-Myc (1:1000). (B) Gelcode Blue-stained 8% SDS-PAGE gel showing that the
pseudo-phosphorylated CEP4 (D/D) co-purified with several protein bands not found with the
phosphorylation-resistant CEP4 (A/A) mutant or VC samples. Bands excised for subsequent MS/MS
analysis are indicated with a carat (<). The results are representative of two independent experiments.
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Table 4.1: MS/MS analysis of proteins that co-immunoprecipitated with TAP-CEP4-18D/80D.
Gel-resolved bands were excised and proteins were digested in situ with trypsin. The resulting
peptides were analyzed by LC−MS/MS on a LTQ Orbitrap mass spectrometer. All MS/MS spectra
were searched against the NCBI database with a probability or significance threshold of P < 0.05
using the automated MASCOT algorithm. (Trypsinolysis and MS/MS analysis were performed at the
Keck Protein Core Facility at Yale University Medical Center.)

Figure 4.15: Western blot verification of protein-protein interactions with CEP4 mutants. A.
MCF-10A cells were transiently transfected with each CEP4 (A/A or D/D) or the vector control (VC).
Following preparation of cell lysates (500 g/sample), co-immunoprecipitation of each CEP4 mutant
was performed with anti-FLAG under non-detergent conditions in order to evaluate binding proteins.
Immunoprecipitated pellets were analyzed by Western blot with either anti-TEM4 (1:500), antiPARD6G (1:500) or anti-Cdc42 (1:500) for studying the protein-protein interaction, and anti-CEP4
(1:2000) as a loading control.
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4.2.7 Characterization of The Function of Phospho-CEP4-associated Protein TEM4 and
Evaluation of Its Potential Role in Rac1 Activation
In order to further elucidate the unknown mechanism underlying Rac1 activation in phosphoCEP4 induced migration, we performed a TAP experiment to identify the phospho-CEP4associated binding proteins, among which were included TEM4 (tumor endothelial marker 4)
and PARD6 (partitioning defective homolog 6 gamma). TEM4 (tumor endothelial marker 4),
also known as ARHGEF17, was identified as a tumor marker protein whose expression was
elevated during cell-induced angiogenesis in endothelial cells (Croix et al., 2000). TEM4 was
previously described as a cytoskeleton binding protein and also associated with the Ecadherin-catenin complex. In confluent cells, TEM4 localizes to cell–cell contacts or actin
stress fibers (Croix et al., 2000). In 2013, Ngok’s group found that TEM4 is a novel Rhospecific GEF (guanine nucleotide exchange factor) in Madin-darby canine kidney (MDCK)
cells. The down-regulation of TEM4 in HUVECs and MDCK cells resulted in defective cellcell junctions and impaired cell morphology (Ngok et al., 2013). Most importantly, TEM4
can regulate endothelial cell migration. Mitin’s group reported that TEM4 provides essential
control of the actin cytoskeleton network, ensures proper membrane protrusion of the leading
edge, and regulates cell migration (Mitin et al., 2013). PARD6G is a 376 amino acid adaptor
protein involved in cell polarization and asymmetrical cell division processes. When atypical
PKC and PARD6G are expressed with constitutively active Rac1, the proteins co-localize to
membrane ruffles. PARD6 also functions as a key adaptor that links Par3 to atypical PKCs
and Cdc42 GTPase (Noda et al., 2001). These interactions are important for the formation or
maintenance of tight junctions in MDCK epithelial cells (Joberty et al., 2000).
Based on these previous studies that showed that TEM4 activates RhoA GTPase, binds actin,
and promotes the migration phenotype, TEM4 was selected for further study as a direct
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binding partner of phospho-CEP4. Thus, TEM4 was evaluated for a role in phospho-CEP4mediated cell motility. The TEM4-specific GFP-shRNA-encoding plasmid was introduced
into MCF-10A cells and the knockdown of TEM4 was achieved with this reagent, as shown
in Figure 4.16A. While TEM4 knockdown was in effect, MCF-10A cells were transfected
with CEP4-18D/80D, CEP4-18A/80A, or VC, and cell migration was assessed. As shown in
Figure 4.16B, silencing of TEM4 resulted in inhibition by almost 40% of the motile behavior
induced by the D/D-CEP4 mutant. Furthermore, the motility of these cells was decreased to
the level of motility of cells expressing the A/A-CEP4 mutant. This result implicates the
TEM4/phospho-CEP4 complex as an active component in the PKC-induced motility
signaling pathway.
The next step was to determine whether phosphorylated CEP4 acts through TEM4 to activate
Rac1. For this purpose, cells were transfected with a CEP4 mutant (or VC) and either TEM4shRNA or the scrambled control shRNA. Following preparation of cell lysates, pull-down of
activated Rac1 was performed with PAK binding domain (PBD)-agarose beads that
specifically bind the activated form of Rac1. Western blot analysis was conducted with a Rac
antibody (recognizes Rac isoforms 1, 2, and 3). As shown in Figure 4.17, when cells
expressed the scrambled control shRNA, the D/D-CEP4 mutant produced a strongly activated
Rac signal as compared with the A/A-CEP4 mutant, or the VC. However, when TEM4 was
silenced, D/D-CEP4 expression did not result in an elevated Rac signal. This finding
implicated phospho-CEP4 or the phospho-CEP4/TEM4 complex in the mechanism by which
Rac was activated.
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Figure 4.16: Differential effects of TEM4 knockdown on migration of CEP4 double mutants in
breast cells. (A) Demonstration that a shRNA reagent knocks down TEM4 expression in MCF-10A
cells. Cells were transfected with the GFP-shRNA-TEM4 plasmid (shRNA) or the GFP-scrambled
control plasmid (SC). After 48 h, cells were transfected with the pseudo-phosphorylated CEP4 double
mutant (D/D), the phosphorylation-resistant CEP4 double mutant (A/A), or the vector control (VC).
Forty-eight h later, cells were lysed, the samples were resolved on a 6% SDS-PAGE gel, and analyzed
for TEM4 expression by Western blot (75 g/lane) with anti-TEM4 (1:500 dilution). The experiment
was performed three times with identical results. (B) MCF-10A transfectants were tested for motility
in triplicate by detecting fluorescent cells expressing either the GFP-shRNA-TEM4 signal (red bars)
or GFP-shRNA-SC (scrambled control) blue bars). Fluorescent images were recorded on a Leica
fluorescence microscope at t = 0 and t = 6 h and the images were quantitated by Motic Image
software. The values are reported as the average of triplicate measurements + s.d. and are
representative of three independent experiments. Statistical analysis was performed with the Student’s
t-test that compared the scrambled control and shRNA condition for each mutant (*P < 0.0001, ** P <
0.000001).

Figure 4.17: Pseudo-phosphorylated CEP4 or TEM4 activates Rac1. Following expression of
either shRNA-TEM4 or the scrambled control shRNA (SC), Rac1 activation was measured in a pulldown assay with 600 g of a lysate prepared from cells co-transfected with the shRNA reagent and
CEP4-S18D/S80D (D/D), CEP4-S18A/S80A (A/A), or the empty vector (VC). Western blot analysis
was performed with anti-Rac (1:500). Total Rac was determined with 70 g of each whole cell lysate.
The results are representative of three independent experiments.
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4.3: Discussion
In the foregoing chapter, CEP4 was characterized as a new substrate of PKC in MCF-10A
human breast cells. The functional significance of phosphorylated CEP4 to specific signaling
events and cancer-related phenotypes were studied. The phosphorylation of CEP4 induced
cell motility which had not been explored in any previous studies of CEP4. Inspection of the
human CEP4 primary sequence shows that there are four independent PKC consensus site
located at Ser-18, Ser-77, Ser-80, and Ser-86. Of these four sites, pseudo-phosphorylated
mutants of CEP4 at only Ser-18 and/or Ser-80 stimulated cell migration (Figure 4.2C). In
complementary experiments, expression of the CEP4-18A/80A (phosphorylation-resistant)
mutant had a dominant negative effect on DAG-lactone stimulated cell motility in MCF-10A
cells (Figure 4.3B). Moreover, the expression of the phosphorylation-resistant mutant CEP418A/80A suppressed DAG-lactone stimulated phosphorylation of endogenous CEP4 protein
(Figure 4.4). These results implicated Ser-18 and Ser-80 as the primary phosphorylation sites
of CEP4 that modify its intracellular functions. The phosphorylation of CEP4 at the both sites
was found to induce the dissociation of CEP4 from constitutively active Cdc42 (Figure 4.9),
and produced elevated cell motility and actin-based membrane protrusions (filopodia) in
MCF-10A cells (Figure 4.6). In the presence of inhibitors of Cdc42 or Rac1, we found that
Rac1 (but not Cdc42) participates in phospho-CEP4-induced cell migration in MCF-10A
cells and filopodia formation (Figure 4.10 and 4.11). The finding that phospho-CEP4
operated independently of Cdc42 to produce these phenotypes, revealed a new dimension in
the function and regulation of this effector protein.
Earlier studies characterized the CEPs as proteins that bind GTP-bound Cdc42 with high
affinity (Hirsch et al., 2001). Cdc42 is bound at the CRIB domain in CEP4 which is located
between Ile27 – Leu53. Therefore, the two sites of phosphorylation identified here (Ser18,
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Ser80) occurred on nearby serine residues that flank this region. In the absence of an
available 3-D structure of CEP4, we can only speculate that the negative charge introduced
by phosphorylation of these Ser residues significantly alters the 3-D structure of the CRIB
domain resulting in severely diminished binding by activated (GTP-bound) Cdc42. Notably,
the other four CEP isoforms do not possess PKC phosphorylation sites (Hirsch et al., 2001),
implying that they are refractory to regulation by PKC.
Since we had identified that phosphorylation of CEP4 causes its disassociation with Cdc42, it
was of interest to determine whether Cdc42 (upon its release from phospho-CEP4) was a
participant in one or both CEP4-induced phenotypes. Although principally known to promote
cell polarity, Cdc42 was reported to suppress migration of breast cancer cells (Zuo et al.,
2012). In the present study, the Cdc42 inhibitor (EMD-Millipore) resulted in a dramatic
stimulation of cell motility regardless of the phosphorylation state of CEP4. These results
implied that a typical role of Cdc42 in MCF-10A cells is to suppress motility. Interestingly,
the Cdc42 inhibitor also eliminated 50% of D/D-CEP4-induced filopodia. Thus, Cdc42 did
not play a role in phospho-CEP4 mediated cell motility. However, Rac1 activity was a crucial
element in the mechanism of CEP4.
Both phenotypic effects (the elevated cell motility and filopodia formation) were impaired by
treatment with a Rac1 inhibitor (Figure 4.10 and 4.11), and suggested that Rac1 is
functionally involved in phospho-CEP4-induced phenotypes. Interestingly, a recent study
from our lab described a model in which PKC-mediated phosphorylation of α-tubulin
promotes numerous, stably elongating MTs that by an unknown mechanism leads to the
formation of GTP-Rac1 and unknown downstream events that promote cell movement (De et
al., 2014). Moreover, an earlier study from our lab showed that Rac1 was also functionally
involved in the motility phenotype produced by PKC-α expression in MCF-10A cells (Sun
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and Rotenberg, 1999). Taken together, our present findings add to this model by including
another PKC substrate that activates Rac1.
Previous studies demonstrated that key components (e.g. integrins) that promote filopodia
formation were also shown to have an important role in cell-cell adhesion (Mattila and
Lappalainen, 2008).

Moreover, filopodia were also shown to contribute to cancer

progression and metastasis (Arjonen et al., 2011). In our study, the formation of filopodia
participates in phospho-CEP4 induced cell motility, and their role in the CEP4 mechanism
provides an area for future investigations.
It is evident that phosphorylation provides a regulatory mechanism that frees CEP4 to engage
in other protein-protein interactions that contribute to motile behavior. The nature of these
interactions was addressed by using the TAP method. With this approach, we identified
TEM4 (ARHGEF17) as a protein that co-purifies and co-immunoprecipitates with D/D-CEP4
from whole cell lysates (Figures 4.14 and 4.15), suggesting that they co-localize in the cell.
TEM4 was linked to the regulation of actin structure (Mitin et al., 2013; Ngok et al., 2013),
and to migration by inhibiting actinomyosin contractility at the leading edge of a moving cell
(Ngok et al., 2013). As a GEF, TEM4 is thought to activate GDP-GTP exchange in RhoA but
not in Rac1 or Cdc42 (Mitin et al., 2013). It is possible that in MCF-10A cells, TEM4 or the
phospho-CEP4/TEM4 complex interacts with an additional unknown component(s) (rather
than Rac1 directly) that in turn produces Rac1 activation. The important finding that
knockdown of TEM4 was sufficient to suppress both motility and Rac1 activation induced by
the D/D-CEP4 mutant to levels produced by the A/A-CEP4 mutant (Figure 4.16 and 4.17),
implicates TEM4 or the TEM4/phospho-CEP4 complex as a component of the PKCstimulated signaling pathway. That motility and filopodia formation are downstream
consequences of Rac1-mediated signaling was indicated by their almost complete elimination
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following treatment with the Rac1-specific inhibitor NSC23766. Because the inhibitor and
Rac antibody used in these studies did not differentiate between Rac1 and Rac3, we cannot
exclude the co-incident involvement of these isoforms, both of which had previously been
implicated in metastatic phenotypes of human breast cells (Baugher et al., 2005).
Taken together, out findings support a model (Figure 6.1) of an emerging PKC signaling
pathway in which PKC-mediated phosphorylation of CEP4 causes its release from GTPCdc42, followed by formation of a complex of phospho-CEP4 with a GEF (e.g. TEM4) that
results in Rac1 activation, membrane protrusion and cell movement.
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Chapter 5: Characterization of CEP4 Mutants in a
Malignant Human Breast Cell Line
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5.1: Introduction
Several protein kinase C (PKC) isoforms were shown to influence different cellular processes
that contribute to the malignancy of human breast cancer cells. The MDA-MB-231 human
breast cancer cell line is one of the most frequently used cell models for human breast cancer.
These cells are referred to as “triple negative” because they lack EGF-receptors, estrogen
receptors, and progesterone receptors, making the cancers they generate difficult to control
(Cailleau et al., 1974). These metastatic cells are intrinsically motile and express high
endogenous levels of active PKC isoforms of which PKC-α is the most abundant. To further
explore the functional significance of phosphorylation of CEP4 at Ser-18 and Ser-80, the
phosphorylation-resistant mutant CEP4-18A/80A was prepared and a possible dominantnegative effect on motility by this mutant was studied in MDA-MB-231 breast tumor cells.

5.2: Results

5.2.1 Generating a MDA-MB-231 Stable Cell Line Expressing Pseudo-Phosphorylated
or Phosphorylation-Resistant Double Mutants of CEP4
To study the impact of CEP4 mutants, MDA-MB-231 cells were stably transfected with
either CEP4-18A/80A or CEP4-18D/80D. The two CEP4 mutants or vector control were
transfected with lipofectamine reagent and the cells were cultured in a selective medium
containing geneticin (G418-sulfate) at a concentration of 500 g/ml. At least two clones were
selected and the expression of CEP4-18A/80A or CEP4-18D/80D in these clones was
confirmed by Western blot (Figure 5.1). Strong signals were detected near 50 kDa with Mycantibody that were not present in cells stably transfected with the vector control.
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Figure 5.1: Expression of pseudo-phosphorylated and phosphorylation-resistant CEP4 mutants
in MDA-MB-231 cells. MDA-MB 231 cells were transfected with CEP4-18D/80D, CEP4-18A/80A
and the empty pCMV6 vector (VC) using lipofectamine transfection reagent (8g:10 l). To generate
stable cell lines, the transfected cells were selected with G418 500 g /ml. Cell extracts from each
stable transfectants were analyzed by Western blot and identified by probing with anti-Myc antibody
(1:1000). -actin (1:5000) served as the loading control.

5.2.2 Characterization of Motility of MDA-MB-231 Cells That Stably Express CEP4
Mutants
Since phospho-CEP4 induced cell migration in MCF-10A cells, we sought to determine
whether the CEP4-18A/80A mutant produced a dominant negative effect on the intrinsic cell
motility of stable transfectants of MDA-MB-231 cells. The cells were seeded through a cell
sedimentation manifold at 7000 cells/well to establish a tight circular confluent monolayer on
a 10-well glass slide pre-coated with 1% BSA. Sixteen hours after seeding, the images of
circle were recorded, followed by another round of image acquisition after 6h. Measurements
were performed using Motic Image software. The difference in the average area of the circles
recorded at t=0h and t=6h was plotted graphically in Figure 5.2. Our results indicated that the
MDA-MB-231 cells stably expressing CEP4-18A/80A exhibited a pronounced inhibition of
migration (by 70%) when compared to cells expressing the pseudo-phosphorylated CEP418D/80D mutant, and fell below the value measured for the vector control.
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Figure 5.2: Phospho-CEP4 enhances cell motility in MDA-MB 231 stable cells. MDA-MB 231
cells were stably transfected with CEP4-18D/80D, CEP4-18A/80A and pCMV6 (vector control).
Motility of each transfectant was measured in triplicate by the cell sedimentation assay (described in
the ‘Methods’), and the values were averaged. Student’s t-test was used to determine the statistical
significance between the CEP4-18D/80D mutant and the vector control (* P<0.001) with n= 9, where
n = number of concentric circles measured per condition.

5.2.3 Characterization of Proliferation Assay for CEP4 Mutants in MDA-MB-231
Stable Cells
As previously shown, the CEP4 mutants in MCF-10A cells did not reveal any difference in
the cell proliferation rate (Figure 4.5). Since this lack of an effect may have been the outcome
of transient transfection, the proliferation assay was performed on the stably transfected
MDA-MB-231 cells. Vector control, CEP4-18D/80D or CEP4-18A/80A stable transfectants
were plated into a 96-well plate. Cell proliferation was measured in a time-dependent
manner. It was noted that CEP4-18A/80A transfectants proliferated faster than CEP418D/80D. This finding suggested that phosphorylation of CEP4 suppresses cell proliferation
and was reminiscent of the suppression of proliferation engendered by PKC- overexpression in MCF-10A cells (Sun and Rotenberg, 1999).
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Figure 5.3: Expression of pseudo-phosphorylated CEP4 inhibits cell proliferation of stably
transfected MDA-MB 231 cells. The proliferation rate of MDA-MB 231 stable transfectants (VC,
CEP4-WT, CEP4-18A-80A and CEP4-18D/80D) was assessed using Alamar Blue reagent, as
described in “Materials and Methods” section. A. The fluorescence intensity was measured over 4
days. Data are expressed as the mean + s.d. of five replicates. B. Proliferation rate was measured by
the slope of the curves in Figure A for different 231 stable transfectants.

5.2.4 Generation of MDA-MB-231/luciferase Stable Cell Lines Expressing CEP4
Mutants
In order to study the effects of CEP4 mutants in a mouse model, we prepared stable cell lines
that constitutively express a CEP4 mutant while co-expressing firefly-luciferase protein in
order to track the mutants in vivo.
MDA-MB-231 cells that stably express CEP4-18D-80D or CEP4-18A-80A (expressed from
a vector bearing a neomycin-resistance gene) were transfected with a pGL4.50 vector
containing the luc gene and the hygromycin-resistance gene. The transfection was conducted
according to the manufacturer’s instructions for lipofectamine 2000. Hygromycin was used to
select for stable clones 48h after transfection. We screened the resulting clones at different
concentrations of hygromycin (100~500 g/ml). Finally, the optimal concentration for
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growing the stable cells was judged to be 400 g/ml for hygromycin and 500g/ml for G418.
Isolation of clonal cells (105cells/ml) was carried out to identify the positive clones by the
presence of luciferase activity (Bright GloTM luciferase assay, Promega). Briefly, 100 l of
each cell suspension was added per well of a 96-well plate in triplicate. Following an
overnight incubation (37oC, 5% CO2), 100 l Bright GloTM reagent (prepared according to the
manufacturer’s protocol) was added to each well and the cells were incubated for 5 minutes
at room temperature. The mixture of reagents and complete medium served as a blank, and
reagents added to MDA-MB-231 parental cells (lacking luciferase and CEP4 mutants) served
as a negative control. The bioluminescence intensity of each clone was measured with a 96well plate reader equipped with a luminometer (SpectraMax M5 microplate reader). In Figure
5.4A, the luminescence data indicated successful stable expression of luciferase protein in
MDA-MB-231 cells expressing either Myc-tagged CEP4-18D/80D or CEP4-18A/80A
mutants. Western blot result probed with anti-Myc confirmed that the positive clones retained
the Myc-tagged CEP4 mutants (Figure 5.4B).
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Figure 5.4: Luminescence assay with MDA-MB-231 cells stably expressing luciferase and either
CEP4-18A/80A or CEP4-18D/80D. A. Cells stably expressing either of the two CEP4 mutants were
transfected with luciferase (Material and Methods), and maintained with hygromycin (400 g/ml)
along with G418 (500 g/ml). The stable cells were plated into a 96-well plate and the luminescence
intensity was recorded by a 96-well plate reader. The luminescence intensity for each construct was
plotted relative to the basal luminescence of MDA-MB-231 parental cells which were assigned an
arbitrary value of 1 (100%). The values are reported as the average of triplicate measurements + s.d.
B. Whole cell lysates (100 g per sample) were prepared to confirm that the stable cell lines still
exhibited CEP4 mutant expression. The blot was probed with polyclonal rabbit Myc antibody
(1:1000, Cell Signaling Technology) to detect the signals of Myc-tagged CEP4. -actin (1:5000, Cell
Signaling Technology) was used as a loading control.
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5.3: Discussion
In this section, we generated MDA-MB-231 stable cell lines carrying the pseudophosphorylated and phosphorylation-resistant CEP4 mutants. The results showed a dominant
negative effect on migration by CEP4-18A/80A (phosphorylation-resistant) in MDA-MB-231
cells. For proliferation, CEP4-18A/80A stimulated cell proliferation compared to the other
constructs. Since the overexpression of PKC-was previously observed to slow down the
proliferation of MCF-10A cells (Sun and Rotenberg, 1999), the present finding implied that
phospho-CEP4 also suppresses the proliferation rate. The CEP4-18D-80D and CEP4-18A80A stable cells will be used to study the behavior of these cells in a three-dimensional
proliferation assay. Three-dimensional (3D) cultures provide a powerful tool that simulates
the in vivo environment (Kenny et al., 2008; Liu et al., 2013). It will be used to study the
differences of the two CEP4 mutants on cell proliferation and invasion and to predict their
behavior in vivo. We also generated a MDA-MB-231 stable cell line carrying CEP4-18D80D/luc or 18A-80A/luc that will be used for assessing tumor growth and metastasis in a
mouse model. Stable expression of the luciferase gene will enable tracking of the
development and spread of breast tumors generated by MDA-MB-231 transfectants and will
reveal the impact of CEP4 phosphorylation on these parameters.
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Chapter 6: Concluding Statement and Future
Directions
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6.1: Concluding Statement
In the late 1970s, Nishizuka and co-workers discovered a new enzyme, Ca2+-activated,
phospholipid-dependent protein kinase – protein kinase C (PKC), which is one of the most
studied enzymes in biology (Nishizuka, 1986). As the major intracellular receptor of tumorpromoting phorbol esters, protein kinase C (PKC) has been studied for decades for its
potential role in carcinogenesis and has been recognized as a potentially important target for
cancer therapeutics (Koivunen et al., 2006; Teicher, 2006; Martiny-Baron and Fabbro, 2007;
Urtreger et al., 2012). PKC isoforms were shown to have different expression profiles and
variable functions during cancer progression of a particular cancer type. PKC isoforms were
shown to be involved in controlling cell proliferation, cell apoptosis, cell polarity and cell
motility in mammalian epithelial cells. Notably, the deregulation of these pathways by PKC
has been observed in breast cancer (Gökmen-Polar et al., 2010; Lønne et al., 2010; Urtreger
et al., 2012). Therefore, PKC is a promising target for blocking breast cancer malignancy.
However, the fact that PKC activity consists of multiple structurally-related isoforms makes
it more difficult to establish the role of a single PKC isoform in breast cancer progression.
For the conventional isoforms, PKC- is still considered as an appropriate target for cancer
therapies especially due to its role in metastasis (Langzam et al., 2001; Kerfoot et al., 2004;
Koivunen et al., 2004; Varga et al., 2004). Representing the novel PKC isoforms, PKC-
inhibits cell apoptosis and promotes metastasis of human breast cancer (Kiley et al., 1999;
Varga et al., 2004; Urtreger et al., 2005; Zeidan et al., 2008; Lønne et al., 2009). Regarding
the potential role of atypical PKC isoforms in breast cancer, evidence links PKC- to
increased proliferative, invasive and metastatic potential of breast cancer cells (Urtreger et
al., 2005; Mustafi et al., 2006; Galvez et al., 2009; Nazarenko et al., 2010). Hence, PKC-, -
and – are prominent targets for breast cancer therapy and predictive markers for breast
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cancer aggressiveness. In view of the importance of PKC activity to cancer progression, very
little is known about PKC substrates that impact cellular transformation. The identification of
physically relevant substrates for each of the three PKC isoforms is very important for a
complete understanding of the mechanisms for isoform-specific PKC regulation in
malignancy and thereby could reveal strategies for the design of an anti-cancer drug.
In the present work, the focus was on the study of PKC substrates in phenotypes of human
breast cancer. The “traceable kinase method” was successfully applied to identify PKC
substrates. This method was introduced in 1997 by K. Shokat who initially used it to identify
protein substrates of v-Src (Shah et al., 1997; Liu et al., 1998b). Several laboratories have
since applied this method to determine the substrates of key protein kinases such as JNK,
ERK2, and Raf-1 (Liu et al., 1998a; Ting et al., 2001; Shah and Shokat, 2002; Böhmer and
Romeis, 2007). In the adaptation of this approach to the study of PKC substrates, our
traceable kinase method involved expression followed by co-immunoprecipitation of the
PKC-, - or – traceable kinase mutants along with any high-affinity substrates bound by
them in MCF-10A human breast cells (Chen et al., 2012). This non-transformed, non-motile
human breast cell line expresses low levels of PKC-α, -δ, and -ζ isoforms therefore providing
an ideal substrate-rich environment in which to identify their protein substrates in response to
a PKC activator (DAG-lactone).
By applying the traceable kinase method, we defined the potential substrate profiles of three
PKC isoforms in MCF-10A human breast cells. Because previous studies demonstrated that
the small GTPase Rac1 has an impact on PKC induced motility, effector and accessory
proteins related to this class of signaling molecule were of primary interest. Among the
potential substrates, we selected ROCK1, CEP4, CLASP1 and PAK2 as our candidates since
they are small GTPase accessory proteins and have been linked to cell motility, invasion or
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metastasis. The in vitro kinase assays ruled out the possibility of ROCK1 and CLASP1
(Figures 3.2, 3.3). Intracellular phosphorylation assays demonstrated that only CEP4
underwent phosphorylation in response to DAG-lactone (Figure 3.4). For PAK2, we found
that PKC- and - phosphorylated PAK2 in vitro but not in non-transformed MCF-10A cells
treated with DAG-lactone. However, in view of the potential of PAK to undergo PKCmediated phosphorylation, a role for phospho-PAK in the invasiveness of breast cancer cells
should be further explored. As a result of these experiments, CEP4 was pursued as a PKC
substrate in human breast cells.
CEP4 belongs to a family of poorly understood effector proteins of Cdc42. To date, the CEP
proteins had been studied as a Cdc42 effector protein in NIH-3T3 fibroblasts and
keratinocytes for their role in regulating the actin cytoskeleton (Joberty et al., 1999; Burbelo
et al., 1999; Hirsch et al., 2001). This study is the first to identify CEP4 as an intracellular
PKC substrate and to characterize the function of phospho-CEP4 in cancer-related
phenotypes of human breast cells.
In the present work, we found that CEP4 serves as substrate for all three PKC isoforms
(PKC-, and -) in MCF-10A cells. Measurements of the stoichiometry of
phosphorylation showed that there might be three to four phosphorylation sites in CEP4
(Figure 3.6, 3.7). By inspection of the CEP4 primary sequence, we found there are four
potential phosphorylation sites – Ser-18, Ser-77, Ser-80 and Ser-86 (Figure 3.5). Among the
four sites we tested, Ser-18 and Ser-80 were found to be the sites whose phosphorylation
impacts CEP4 function (Figure 4.2, 4.3, 4.4). Therefore, CEP4 was prepared as a pseudophosphorylated mutant (S18D/S80D)-CEP4 to establish the function of phospho-CEP4, and
S18A/80A was constructed as a phosphorylation-resistant mutant to block the effect of PKC
on associated phenotypes. As shown in Chapter 4, CEP4-S18D/80D stimulated cell motility

98

and induced filopodia in MCF-10A cells (Figure 4.2, 4.6). To further explore the mechanism
of the phospho-CEP4-induced phenotype, we determined whether phosphorylation of CEP4
influences its affinity for Cdc42. The result demonstrated that phospho-CEP4 is largely
dissociated from Cdc42 (Figure 4.9). This finding opened up two lines of inquiry: (1) the
released Cdc42 could become activated, resulting in stimulated cell motility and filopodia; or
(2) phospho-CEP4 itself could interact with other proteins involved in cell motility and
formation of filopodia. To examine the two possibilities, pseudo-phosphorylated CEP4 was
tested on motility in the presence of a Cdc42 inhibitor-ML141. The outcome indicated that
Cdc42 seems not to be involved in motility and might be related to a limited extent in
filopodia formation (Figure 4.10A and 4.11). Based on our previous studies, Rac1 was
functionally involved in the motility phenotype produced by PKC-α expression in MCF-10A
cells. There is therefore a strong possibility that Rac1 is also involved in phospho-CEP4mediated motility. In order to test this idea, we investigated the function of Rac1 in phosphoCEP4-related phenotypes. A Rac1 inhibitor was found to eliminate cell motility and the
formation of filopodia produced by phospho-CEP4 (Figure 4.10B, 4.11). Although it was
shown previously that CEP4 does not bind constitutively active Rac1, an enhanced binding
affinity of pseudo-phosphorylated CEP4 for constitutively active Rac1 remains an untested
possibility. Alternatively, proteins associated with phospho-CEP4 (and not unphosphorylated
CEP4) might interact with Rac1 and thereby regulate Rac1. In this regard, we found that
TEM4 interacts directly with phospho-CEP4 (Figure 4.14 and 4.15). Interestingly, the
knockdown of TEM4 was sufficient to suppress both motility and Rac1 activation induced by
the D/D-CEP4 mutant to levels produced by the A/A-CEP4 mutant (Figure 4.16 and 4.17).
Thus, TEM4/phospho-CEP4 complex plays an important role in phospho-CEP4 induced
activation of Rac1 and cell motility.
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The studies presented in this dissertation are innovative because they are the first to identify
CEP4 as a PKC substrate and the first indication of the functional significance of phosphoCEP4 in human breast cells. This study provides a model that describes how PKC activation
in human breast cell lines unleashes a sequence of events that result in cell movement. The
phosphorylation of a PKC substrate such as CEP4 is likely to promote its association with
other proteins that culminate in Rac1 activation (Figure 6.1). The following proposed studies
may further elucidate the complete model and test our findings in an animal model.

Figure 6.1: Model of PKC-mediated phosphorylation of CEP4 and its consequences. PKC
isoforms phosphorylate CEP4 leading to its dissociation from Cdc42. Phospho-CEP4 binds to TEM4
that in turn stimulates GDP-GTP exchange in Rac1 and leads to downstream events supporting
motility and filopodia formation.

6.2: Future Studies
6.2.1: Evaluation of the Functional Significance of IQGAP1 and PAK2 as PKC
Substrates
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IQGAP1 is an actin binding protein involved in regulating various cellular processes like
organization of the actin cytoskeleton, cellular adhesion and cell migration (Brandt and
Grosse, 2007; Jadeski et al., 2008; Johnson et al., 2009; White et al., 2009). IQGAP1 is also
considered as an oncogene, since it participates in cancer cell invasion and metastasis, and its
expression is up-regulated in various invasive human cancers (Dong et al. 2006). IQGAP1,
acting as an effector protein for Cdc42 and Rac1 effector, inhibits the GTPase activity of
Cdc42 and Rac1 by stabilizing their GTP-bound form, and is consistent with their
involvement in actin-dependent functions such as cell shape and motility (Bashour et al.
1997). IQGAP1 also has been identified as a PKC substrate that undergoes phosphorylation
at Ser-1443 in cells (Grohmanova et al., 2004). As a PKC substrate, IQGAP1 has not yet
been studied. Since one phosphorylation site has been discovered, the pseudo-phosphorylated
and phosphorylation-resistant mutants can be prepared and the functional significance (to
motility and organization of actin filaments) will be investigated in MCF-10A cells. The
possibility of additional phosphorylation sites can also be explored by mutation of PKC
consensus sites.
PAK2 belongs to the p21-activated protein kinase (PAK) family which is known to be
involved in numerous biological functions, including cytoskeletal organization, cell motility,
cell growth and apoptosis. The PAK family members are serine/threonine protein kinases that
serve as major downstream targets of the small G proteins Cdc42 and Rac1 (Bagrodia and
Cerione, 1999). Evidences have been shown that PAK2 is required for the generation of focal
adhesions and is implicated in controlling membrane and cell shape. However, in the present
work, PAK2 was phosphorylated in vitro but not in MCF-10A cells. The potential of
phospho-PAK2 in motile cells such as metastatic cancer cells provides an avenue for future
investigation.

101

Figure 6.2: Known and potential PKC substrates have been characterized in the Rotenberg lab.

6.2.2: Elucidation of the PKC signaling pathway
Because of the importance of PKC in cancer metastasis, it is essential to identify PKC
substrates and to interpret the role of substrates as components of PKC signaling pathway(s).
In view of the multi-focal effects of PKC in cancer cells, the understanding of a PKC
signaling pathway greatly facilitates the discovery of anti-cancer drugs and therapies. In an
effort to elucidate the components of the PKC signaling pathway, recent studies from the
Rotenberg lab identified tubulin as a PKC substrate (De et al. 2014). Phosphorylation of
-tubulin at a single site (Ser165) results in its increased incorporation into microtubules that
promotes increased interactions by microtubules with the membrane that in turn produced
activation of Rac1 and increased motility (De et al., 2014). That D/D-CEP4 co-purifies with
CLIP1, a microtubule plus-end binding protein, suggests a possible interaction of phosphoCEP4 with elongating microtubules that produce Rac1 activation. Whatever the mechanism,
Rac1 serves as a point of convergence by at least two PKC substrates, underscoring the
importance of Rac1-associated GEFs (and GAPs) to both motility signaling and membrane
protrusions in breast cancer (Parri and Chiarugi, 2010; Sosa and Kazanietz, 2012). In view of
the fact that -tubulin and CEP4 are both highly abundant PKC substrates that promote
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signaling through Rac1, we speculate that their co-incident phosphorylation by PKC could
lead to continuous GDP-GTP exchange on Rac1 that consequently gives rise to aggressive
cell movement. Future work will try to investigate other PKC substrates such as MARCKS,
PAK2, and IQGAP1 to determine whether they also contribute to this pathway. Moreover,
after elucidation of the PKC signaling pathway, inhibition of one or more certain targets in
this pathway by rationally designed inhibitors can be tested for its inhibition of PKC induced
cell migration and evaluated for preventing cancer metastasis in an animal model.

6.2.3: Investigation of CEP4 or Other PKC Substrates in a Three Dimensional (3D)
Assay and Its Contribution to Mammary Tumor Development
A 3D cell culture is an artificially-created environment that closely resembles natural tissue
(Liu et al., 2013). A three-dimensional 3D matrix retains the biophysical and biomechanical
signals that affect cell functions such as proliferation, migration, adhesion and gene
expression (Kenny et al., 2008; Graf and Boppart, 2010). Therefore, in order to study the
effect of phospho-CEP4 on cell migration, morphogenesis, and proliferation, a 3-D cell
culture assay is predictive of the impact of CEP4 within the in vivo environment.
The MDA-MB-231-luc stable cell lines expressing CEP4-18A/80A or CEP4-18D/80D were
generated and will be used to track tumorigenesis and metastasis of these cells in an
orthotopic mouse model. MDA-MB-231-luc cells bearing either CEP4-18A/80A or CEP4S18D/S80D will be implanted into the fat pads of a nude mouse. The growth and spread of
the resulting tumors will be monitored using the luciferase reporter gene in vivo by
bioluminescence imaging technology (IVIS). Isolation of the resulting tumors will be
followed by establishing Myc-CEP4 mutant expression by Western blot, RT/PCR, and
immunohistochemistry (Frick et al., 2013). The animal work will help to establish the role of
phospho-CEP4 in vivo.
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